1,101 results on '"van Ree, R"'
Search Results
152. Allergen immunotherapy for IgE-mediated food allergy : a systematic review and meta-analysis
- Author
-
Nurmatov, U., Dhami, S., Arasi, S., Pajno, G. B., Fernandez-Rivas, M., Muraro, A., Roberts, G., Akdis, C., Alvaro-Lozano, M., Beyer, K., Bindslev-Jensen, C., Burks, W., du Toit, G., Ebisawa, M., Eigenmann, P., Knol, E., Mäkelä, Mika, Nadeau, K. C., O'Mahony, L., Papadopoulos, N., Poulsen, L. K., Sackesen, C., Sampson, H., Santos, A. F., van Ree, R., Timmermans, F., Sheikh, A., Clinicum, Department of Dermatology, Allergology and Venereology, and HUS Inflammation Center
- Subjects
safety ,ORAL TOLERANCE INDUCTION ,food allergy ,PEANUT ALLERGY ,desensitization ,CHILDREN ,CONTROLLED-TRIAL ,DOUBLE-BLIND ,EGG ALLERGY ,SUBLINGUAL IMMUNOTHERAPY ,3121 General medicine, internal medicine and other clinical medicine ,sustained unresponsiveness ,COWS MILK ALLERGY ,allergen immunotherapy ,ANAPHYLACTIC REACTIONS - Abstract
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines for Allergen Immunotherapy (AIT) for IgE-mediated Food Allergy. To inform the development of clinical recommendations, we sought to critically assess evidence on the effectiveness, safety and cost-effectiveness of AIT in the management of food allergy. Methods: We undertook a systematic review and meta-analysis that involved searching nine international electronic databases for randomized controlled trials (RCTs) and nonrandomized studies (NRS). Eligible studies were independently assessed by two reviewers against predefined eligibility criteria. The quality of studies was assessed using the Cochrane Risk of Bias tool for RCTs and the Cochrane ACROBAT-NRS tool for quasi-RCTs. Random-effects meta-analyses were undertaken, with planned subgroup and sensitivity analyses. Results: We identified 1814 potentially relevant papers from which we selected 31 eligible studies, comprising of 25 RCTs and six NRS, studying a total of 1259 patients. Twenty-five trials evaluated oral immunotherapy (OIT), five studies investigated sublingual immunotherapy, and one study evaluated epicutaneous immunotherapy. The majority of these studies were in children. Twenty-seven studies assessed desensitization, and eight studies investigated sustained unresponsiveness postdiscontinuation of AIT. Meta-analyses demonstrated a substantial benefit in terms of desensitization (risk ratio (RR) = 0.16, 95% CI 0.10, 0.26) and suggested, but did not confirm sustained unresponsiveness (RR = 0.29, 95% CI 0.08, 1.13). Only one study reported on disease-specific quality of life (QoL), which reported no comparative results between OIT and control group. Meta-analyses revealed that the risk of experiencing a systemic adverse reaction was higher in those receiving AIT, with a more marked increase in the risk of local adverse reactions. Sensitivity analysis excluding those studies judged to be at high risk of bias demonstrated the robustness of summary estimates of effectiveness and safety of AIT for food allergy. None of the studies reported data on health economic analyses. Conclusions: AIT may be effective in raising the threshold of reactivity to a range of foods in children with IgE-mediated food allergy whilst receiving (i.e. desensitization) and post-discontinuation of AIT. It is, however, associated with a modest increased risk in serious systemic adverse reactions and a substantial increase in minor local adverse reactions. More data are needed in relation to adults, long term effects, the impact on QoL and the cost-effectiveness of AIT.
- Published
- 2017
153. The urgent need for a harmonized severity scoring system for acute allergic reactions
- Author
-
Muraro, A., primary, Fernandez-Rivas, M., additional, Beyer, K., additional, Cardona, V., additional, Clark, A., additional, Eller, E., additional, Hourihane, J. O'B., additional, Jutel, M., additional, Sheikh, A., additional, Agache, I., additional, Allen, K. J., additional, Angier, E., additional, Ballmer-Weber, B., additional, Bilò, M. B., additional, Bindslev-Jensen, C., additional, Camargo, C. A., additional, Cianferoni, A., additional, DunnGalvin, A., additional, Eigenmann, P. A., additional, Halken, S., additional, Hoffmann-Sommergruber, K., additional, Lau, S., additional, Nilsson, C., additional, Poulsen, L. K., additional, Rueff, F., additional, Spergel, J., additional, Sturm, G., additional, Timmermans, F., additional, Torres, M. J., additional, Turner, P., additional, van Ree, R., additional, Wickman, M., additional, Worm, M., additional, Mills, E. N. C., additional, and Roberts, G., additional
- Published
- 2018
- Full Text
- View/download PDF
154. EAACI guidelines on allergen immunotherapy: Executive statement
- Author
-
Muraro, A., primary, Roberts, G., additional, Halken, S., additional, Agache, I., additional, Angier, E., additional, Fernandez‐Rivas, M., additional, Gerth van Wijk, R., additional, Jutel, M., additional, Lau, S., additional, Pajno, G., additional, Pfaar, O., additional, Ryan, D., additional, Sturm, G. J., additional, van Ree, R., additional, Varga, E.‐M., additional, Bachert, C., additional, Calderon, M., additional, Canonica, G. W., additional, Durham, S. R., additional, Malling, H. J., additional, Wahn, U., additional, and Sheikh, A., additional
- Published
- 2018
- Full Text
- View/download PDF
155. The urgent need for a harmonized severity scoring system for acute allergic reactions
- Author
-
Muraro, A, Fernandez-Rivas, M, Beyer, K, Cardona, V, Clark, A, Eller, E, Hourihane, JO, Jutel, M, Sheikh, A, Agache, I, Allen, KJ, Angier, E, Ballmer-Weber, B, Bilo, MB, Bindslev-Jensen, C, Camargo, CA, Cianferoni, A, DunnGalvin, A, Eigenmann, PA, Halken, S, Hoffmann-Sommergruber, K, Lau, S, Nilsson, C, Poulsen, LK, Rueff, F, Spergel, J, Sturm, G, Timmermans, F, Torres, MJ, Turner, P, van Ree, R, Wickman, M, Worm, M, Mills, ENC, Roberts, G, Muraro, A, Fernandez-Rivas, M, Beyer, K, Cardona, V, Clark, A, Eller, E, Hourihane, JO, Jutel, M, Sheikh, A, Agache, I, Allen, KJ, Angier, E, Ballmer-Weber, B, Bilo, MB, Bindslev-Jensen, C, Camargo, CA, Cianferoni, A, DunnGalvin, A, Eigenmann, PA, Halken, S, Hoffmann-Sommergruber, K, Lau, S, Nilsson, C, Poulsen, LK, Rueff, F, Spergel, J, Sturm, G, Timmermans, F, Torres, MJ, Turner, P, van Ree, R, Wickman, M, Worm, M, Mills, ENC, and Roberts, G
- Abstract
The accurate assessment and communication of the severity of acute allergic reactions are important to patients, clinicians, researchers, the food industry, and public health and regulatory authorities. Severity has different meanings to different stakeholders with patients and clinicians rating the significance of particular symptoms very differently. Many severity scoring systems have been generated, most focusing on the severity of reactions following exposure to a limited group of allergens. They are heterogeneous in format, none has used an accepted developmental approach, and none has been validated. Their wide range of outcome formats has led to difficulties with interpretation and application. Therefore, there is a persisting need for an appropriately developed and validated severity scoring system for allergic reactions that work across the range of allergenic triggers and address the needs of different stakeholder groups. We propose a novel approach to develop and then validate a harmonized scoring system for acute allergic reactions, based on a data-driven method that is informed by clinical and patient experience and other stakeholders' perspectives. We envisage two formats: (i) a numerical score giving a continuum from mild to severe reactions that are clinically meaningful and are useful for allergy healthcare professionals and researchers, and (ii) a three-grade-based ordinal format that is simple enough to be used and understood by other professionals and patients. Testing of reliability and validity of the new approach in a range of settings and populations will allow eventual implementation of a standardized scoring system in clinical studies and routine practice.
- Published
- 2018
156. Component-resolved diagnosis and beyond: Multivariable regression models to predict severity of hazelnut allergy
- Author
-
Arts-assistenten Kinderen, MS Dermatologie/Allergologie, Infection & Immunity, Datema, M. R., van Ree, R., Asero, R., Barreales, L., Belohlavkova, S., de Blay, F., Clausen, M., Dubakiene, R., Fernández-Perez, C., Fritsche, P., Gislason, D., Hoffmann-Sommergruber, K., Jedrzejczak-Czechowicz, M., Jongejan, L., Knulst, A. C., Kowalski, M., Kralimarkova, T. Z., Le, T. M., Lidholm, J., Papadopoulos, N. G., Popov, T. A., del Prado, N., Purohit, A., Reig, I., Seneviratne, S. L., Sinaniotis, A., Versteeg, S. A., Vieths, S., Zwinderman, A. H., Mills, E. N.C., Fernández-Rivas, M., Ballmer-Weber, B., Arts-assistenten Kinderen, MS Dermatologie/Allergologie, Infection & Immunity, Datema, M. R., van Ree, R., Asero, R., Barreales, L., Belohlavkova, S., de Blay, F., Clausen, M., Dubakiene, R., Fernández-Perez, C., Fritsche, P., Gislason, D., Hoffmann-Sommergruber, K., Jedrzejczak-Czechowicz, M., Jongejan, L., Knulst, A. C., Kowalski, M., Kralimarkova, T. Z., Le, T. M., Lidholm, J., Papadopoulos, N. G., Popov, T. A., del Prado, N., Purohit, A., Reig, I., Seneviratne, S. L., Sinaniotis, A., Versteeg, S. A., Vieths, S., Zwinderman, A. H., Mills, E. N.C., Fernández-Rivas, M., and Ballmer-Weber, B.
- Published
- 2018
157. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States:An analysis from the EAACI AIT Guidelines Project
- Author
-
Bonertz, A, Roberts, G, Slater, J E, Bridgewater, J, Rabin, R L, Hoefnagel, M, Timon, M, Pini, C, Pfaar, O, Sheikh, A, Ryan, D, Akdis, C, Goldstein, J, Poulsen, L K, van Ree, R, Rhyner, C, Barber, D, Palomares, O, Pawankar, R, Hamerlijnk, D, Klimek, L, Agache, I, Angier, E, Casale, T, Fernandez-Rivas, M, Halken, S, Jutel, M, Pajno, G, Sturm, G, Varga, E M, Gerth van Wijk, R, Bonini, S, Muraro, A, Vieths, S, Bonertz, A, Roberts, G, Slater, J E, Bridgewater, J, Rabin, R L, Hoefnagel, M, Timon, M, Pini, C, Pfaar, O, Sheikh, A, Ryan, D, Akdis, C, Goldstein, J, Poulsen, L K, van Ree, R, Rhyner, C, Barber, D, Palomares, O, Pawankar, R, Hamerlijnk, D, Klimek, L, Agache, I, Angier, E, Casale, T, Fernandez-Rivas, M, Halken, S, Jutel, M, Pajno, G, Sturm, G, Varga, E M, Gerth van Wijk, R, Bonini, S, Muraro, A, and Vieths, S
- Abstract
Adequate quality is essential for any medicinal product to be eligible for marketing. Quality includes verification of the identity, content and purity of a medicinal product in combination with a specified production process and its control. Allergen products derived from natural sources require particular considerations to ensure adequate quality. Here, we describe key aspects of the documentation on manufacturing and quality aspects for allergen immunotherapy products in the European Union and the United States. In some key parts, requirements in these areas are harmonized while other fields are regulated separately between both regions. Essential differences are found in the use of Reference Preparations, or the requirement to apply standardized assays for potency determination. As the types of products available are different in specific regions, regulatory guidance for such products may also be available in one specific region only, such as for allergoids in the European Union. Region-specific issues and priorities are a result of this. As allergen products derived from natural sources are inherently variable in their qualitative and quantitative composition, these products present special challenges to balance the variability and ensuring batch-to-batch consistency. Advancements in scientific knowledge on specific allergens and their role in allergic disease will consequentially find representation in future regulatory guidelines.
- Published
- 2018
158. A comparative study on basophil activation test, histamine release assay, and passive sensitization histamine release assay in the diagnosis of peanut allergy
- Author
-
Larsen, L F, Juel-Berg, N, Hansen, K S, Clare Mills, E N, van Ree, R, Poulsen, L K, Jensen, B M, Larsen, L F, Juel-Berg, N, Hansen, K S, Clare Mills, E N, van Ree, R, Poulsen, L K, and Jensen, B M
- Abstract
BACKGROUND: Allergy can be diagnosed using basophil tests. Several methods measuring basophil activation are available. This study aimed at comparing basophil activation test (BAT), histamine release assay (HR), and passive sensitization histamine release assay (passive HR) in the diagnosis of peanut allergy.METHODS: BAT, HR, and passive HR were performed on 11 peanut-allergic and 14 nonallergic subjects. Blood was incubated with peanut extract or anti-IgE and tests were performed as follows: BAT-CD63 upregulation was assessed by flow cytometry; HR-released histamine was quantified by a glass fiber-based fluorometric method; passive HR-IgE-stripped donor basophils were incubated with participants' serum and histamine release was quantified as HR.RESULTS: CDsens, a measure of basophil allergen sensitivity, was significantly higher for BAT (80.1±17.4) compared to HR (23.4±10.31) and passive HR (11.1±2.0). BAT, HR, and passive HR had a clinical sensitivity of 100%, 100%, and 82% and specificity of 100%, 100%, and 100%, respectively, when excluding inconclusive results. BAT identified 11 of 11 allergic patients, HR 10, and passive HR 9. Likewise, BAT recognized 12 of 14 nonallergic subjects, HR 10, and passive HR 13. However, the tests' diagnostic performances were not statistically different. Interestingly, nonreleasers in HR but not in BAT had lower basophil count compared to releasers (249 vs 630 counts/min).CONCLUSION: BAT displayed a significantly higher CDsens compared to HR and passive HR. The basophil tests' diagnostic performances were not significantly different. Still, BAT could diagnose subjects with low basophil number in contrast to HR.
- Published
- 2018
159. EAACI Guidelines on allergen immunotherapy:IgE-mediated food allergy
- Author
-
Pajno, G. B., Fernandez-Rivas, M., Arasi, S., Roberts, G., Akdis, C. A., Alvaro-Lozano, M., Beyer, K., Bindslev-Jensen, C., Burks, W., Ebisawa, M., Eigenmann, P., Knol, E., Nadeau, K. C., Poulsen, L. K., van Ree, R., Santos, A. F., du Toit, G., Dhami, S., Nurmatov, U., Boloh, Y., Makela, M., O'Mahony, L., Papadopoulos, N., Sackesen, C., Agache, I., Angier, E., Halken, S., Jutel, M., Lau, S., Pfaar, O., Ryan, D., Sturm, G., Varga, E. M., van Wijk, R. G., Sheikh, A., Muraro, A., Pajno, G. B., Fernandez-Rivas, M., Arasi, S., Roberts, G., Akdis, C. A., Alvaro-Lozano, M., Beyer, K., Bindslev-Jensen, C., Burks, W., Ebisawa, M., Eigenmann, P., Knol, E., Nadeau, K. C., Poulsen, L. K., van Ree, R., Santos, A. F., du Toit, G., Dhami, S., Nurmatov, U., Boloh, Y., Makela, M., O'Mahony, L., Papadopoulos, N., Sackesen, C., Agache, I., Angier, E., Halken, S., Jutel, M., Lau, S., Pfaar, O., Ryan, D., Sturm, G., Varga, E. M., van Wijk, R. G., Sheikh, A., and Muraro, A.
- Abstract
Food allergy can result in considerable morbidity, impairment of quality of life, and healthcare expenditure. There is therefore interest in novel strategies for its treatment, particularly food allergen immunotherapy (FA-AIT) through the oral (OIT), sublingual (SLIT), or epicutaneous (EPIT) routes. This Guideline, prepared by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force on Allergen Immunotherapy for IgE-mediated Food Allergy, aims to provide evidence-based recommendations for active treatment of IgE-mediated food allergy with FA-AIT. Immunotherapy relies on the delivery of gradually increasing doses of specific allergen to increase the threshold of reaction while on therapy (also known as desensitization) and ultimately to achieve post-discontinuation effectiveness (also known as tolerance or sustained unresponsiveness). Oral FA-AIT has most frequently been assessed: here, the allergen is either immediately swallowed (OIT) or held under the tongue for a period of time (SLIT). Overall, trials have found substantial benefit for patients undergoing either OIT or SLIT with respect to efficacy during treatment, particularly for cow's milk, hen's egg, and peanut allergies. A benefit post-discontinuation is also suggested, but not confirmed. Adverse events during FA-AIT have been frequently reported, but few subjects discontinue FA-AIT as a result of these. Taking into account the current evidence, FA-AIT should only be performed in research centers or in clinical centers with an extensive experience in FA-AIT. Patients and their families should be provided with information about the use of FA-AIT for IgE-mediated food allergy to allow them to make an informed decision about the therapy.
- Published
- 2018
160. Challenges in the implementation of EAACI guidelines on allergen immunotherapy:A global perspective on the regulation of allergen products
- Author
-
Bonertz, A, Roberts, G C, Hoefnagel, M, Timon, M, Slater, J E, Rabin, R L, Bridgewater, J, Pini, C, Pfaar, O, Akdis, C, Goldstein, J, Poulsen, L K, van Ree, R, Rhyner, C, Barber, D, Palomares, O, Sheikh, A, Pawankar, R, Hamerlijnk, D, Klimek, L, Agache, I, Angier, E, Casale, T, Fernandez-Rivas, M, Halken, S, Jutel, M, Lau, S, Pajno, G, Sturm, G, Varga, E M, Gerth van Wijk, R, Bonini, S, Muraro, A, Vieths, S, Bonertz, A, Roberts, G C, Hoefnagel, M, Timon, M, Slater, J E, Rabin, R L, Bridgewater, J, Pini, C, Pfaar, O, Akdis, C, Goldstein, J, Poulsen, L K, van Ree, R, Rhyner, C, Barber, D, Palomares, O, Sheikh, A, Pawankar, R, Hamerlijnk, D, Klimek, L, Agache, I, Angier, E, Casale, T, Fernandez-Rivas, M, Halken, S, Jutel, M, Lau, S, Pajno, G, Sturm, G, Varga, E M, Gerth van Wijk, R, Bonini, S, Muraro, A, and Vieths, S
- Abstract
Regulatory approaches for allergen immunotherapy (AIT) products and the availability of high-quality AIT products are inherently linked to each other. While allergen products are available in many countries across the globe, their regulation is very heterogeneous. First, we describe the regulatory systems applicable for AIT products in the European Union (EU) and in the United States (US). For Europe, a depiction of the different types of relevant procedures, as well as the committees involved, is provided and the fundamental role of national agencies of the EU member states in this complex and unique network is highlighted. Furthermore, the regulatory agencies from Australia, Canada, Japan, Russia, and Switzerland provided information on the system implemented in their countries for the regulation of allergen products. While AIT products are commonly classified as biological medicinal products, they are made available by varying types of procedures, most commonly either by obtaining a marketing authorization or by being distributed as named patient products. Exemptions from marketing authorizations in exceptional cases, as well as import of allergen products from other countries, are additional tools applied by countries to ensure availability of needed AIT products. Several challenges for AIT products are apparent from this analysis and will require further consideration.
- Published
- 2018
161. Challenges in the implementation of the EAACI AIT guidelines:A situational analysis of current provision of allergen immunotherapy
- Author
-
Ryan, D, Gerth van Wijk, R, Angier, E, Kristiansen, Maria, Zaman, H, Sheikh, A, Cardona, V, Vidal, C, Warner, A, Agache, I, Arasi, S, Fernandez-Rivas, M, Halken, S, Jutel, M, Lau, S, Pajno, G, Pfaar, O, Roberts, G, Sturm, G, Varga, E M, Van Ree, R, Muraro, A, Ryan, D, Gerth van Wijk, R, Angier, E, Kristiansen, Maria, Zaman, H, Sheikh, A, Cardona, V, Vidal, C, Warner, A, Agache, I, Arasi, S, Fernandez-Rivas, M, Halken, S, Jutel, M, Lau, S, Pajno, G, Pfaar, O, Roberts, G, Sturm, G, Varga, E M, Van Ree, R, and Muraro, A
- Abstract
PURPOSE: The European Academy of Allergy and Clinical Immunology (EAACI) has produced Guidelines on Allergen Immunotherapy (AIT). We sought to gauge the preparedness of primary care to participate in the delivery of AIT in Europe.METHODS: We undertook a mixed-methods, situational analysis. This involved a purposeful literature search and two surveys: one to primary care clinicians and the other to a wider group of stakeholders across Europe.RESULTS: The 10 papers identified all pointed out gaps or deficiencies in allergy care provision in primary care. The surveys also highlighted similar concerns, particularly in relation to concerns about lack of knowledge, skills, infrastructural weaknesses, reimbursement policies and communication with specialists as barriers to evidence-based care. Almost all countries (92%) reported the availability of AIT. In spite of that, only 28% and 44% of the countries reported the availability of guidelines for primary care physicians and specialists, respectively. Agreed pathways between specialists and primary care physicians were reported as existing in 32%-48% of countries. Reimbursement appeared to be an important barrier as AIT was only fully reimbursed in 32% of countries. Additionally, 44% of respondents considered accessibility to AIT and 36% stating patient costs were barriers.CONCLUSIONS: Successful working with primary care providers is essential to scaling-up AIT provision in Europe, but to achieve this, the identified barriers must be overcome. Development of primary care interpretation of guidelines to aid patient selection, establishment of disease management pathways and collaboration with specialist groups are required as a matter of urgency.
- Published
- 2018
162. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis
- Author
-
Nurmatov, U. Dhami, S. Arasi, S. Pajno, G.B. Fernandez-Rivas, M. Muraro, A. Roberts, G. Akdis, C. Alvaro-Lozano, M. Beyer, K. Bindslev-Jensen, C. Burks, W. du Toit, G. Ebisawa, M. Eigenmann, P. Knol, E. Makela, M. Nadeau, K.C. O'Mahony, L. Papadopoulos, N. Poulsen, L.K. Sackesen, C. Sampson, H. Santos, A.F. van Ree, R. Timmermans, F. Sheikh, A.
- Abstract
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines for Allergen Immunotherapy (AIT) for IgE-mediated Food Allergy. To inform the development of clinical recommendations, we sought to critically assess evidence on the effectiveness, safety and cost-effectiveness of AIT in the management of food allergy. Methods: We undertook a systematic review and meta-analysis that involved searching nine international electronic databases for randomized controlled trials (RCTs) and nonrandomized studies (NRS). Eligible studies were independently assessed by two reviewers against predefined eligibility criteria. The quality of studies was assessed using the Cochrane Risk of Bias tool for RCTs and the Cochrane ACROBAT-NRS tool for quasi-RCTs. Random-effects meta-analyses were undertaken, with planned subgroup and sensitivity analyses. Results: We identified 1814 potentially relevant papers from which we selected 31 eligible studies, comprising of 25 RCTs and six NRS, studying a total of 1259 patients. Twenty-five trials evaluated oral immunotherapy (OIT), five studies investigated sublingual immunotherapy, and one study evaluated epicutaneous immunotherapy. The majority of these studies were in children. Twenty-seven studies assessed desensitization, and eight studies investigated sustained unresponsiveness postdiscontinuation of AIT. Meta-analyses demonstrated a substantial benefit in terms of desensitization (risk ratio (RR) = 0.16, 95% CI 0.10, 0.26) and suggested, but did not confirm sustained unresponsiveness (RR = 0.29, 95% CI 0.08, 1.13). Only one study reported on disease-specific quality of life (QoL), which reported no comparative results between OIT and control group. Meta-analyses revealed that the risk of experiencing a systemic adverse reaction was higher in those receiving AIT, with a more marked increase in the risk of local adverse reactions. Sensitivity analysis excluding those studies judged to be at high risk of bias demonstrated the robustness of summary estimates of effectiveness and safety of AIT for food allergy. None of the studies reported data on health economic analyses. Conclusions: AIT may be effective in raising the threshold of reactivity to a range of foods in children with IgE-mediated food allergy whilst receiving (i.e. desensitization) and post-discontinuation of AIT. It is, however, associated with a modest increased risk in serious systemic adverse reactions and a substantial increase in minor local adverse reactions. More data are needed in relation to adults, long term effects, the impact on QoL and the cost-effectiveness of AIT. © 2017 The Authors. Allergy Published by John Wiley & Sons Ltd.
- Published
- 2017
163. A new framework for the documentation and interpretation of oral food challenges in population-based and clinical research
- Author
-
Grabenhenrich, L.B. Reich, A. Bellach, J. Trendelenburg, V. Sprikkelman, A.B. Roberts, G. Grimshaw, K.E.C. Sigurdardottir, S. Kowalski, M.L. Papadopoulos, N.G. Quirce, S. Dubakiene, R. Niggemann, B. Fernández-Rivas, M. Ballmer-Weber, B. van Ree, R. Schnadt, S. Mills, E.N.C. Keil, T. Beyer, K.
- Abstract
Background: The conduct of oral food challenges as the preferred diagnostic standard for food allergy (FA) was harmonized over the last years. However, documentation and interpretation of challenge results, particularly in research settings, are not sufficiently standardized to allow valid comparisons between studies. Our aim was to develop a diagnostic toolbox to capture and report clinical observations in double-blind placebo-controlled food challenges (DBPCFC). Methods: A group of experienced allergists, paediatricians, dieticians, epidemiologists and data managers developed generic case report forms and standard operating procedures for DBPCFCs and piloted them in three clinical centres. The follow-up of the EuroPrevall/iFAAM birth cohort and other iFAAM work packages applied these methods. Recommendations: A set of newly developed questionnaire or interview items capture the history of FA. Together with sensitization status, this forms the basis for the decision to perform a DBPCFC, following a standardized decision algorithm. A generic form including details about severity and timing captures signs and symptoms observed during or after the procedures. In contrast to the commonly used dichotomous outcome FA vs no FA, the allergy status is interpreted in multiple categories to reflect the complexity of clinical decision-making. Conclusion: The proposed toolbox sets a standard for improved documentation and harmonized interpretation of DBPCFCs. By a detailed documentation and common terminology for communicating outcomes, these tools hope to reduce the influence of subjective judgment of supervising physicians. All forms are publicly available for further evolution and free use in clinical and research settings. © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd.
- Published
- 2017
164. Supplementary Material for: Development of a Hypoallergenic Recombinant Parvalbumin for First-in-Man Subcutaneous Immunotherapy of Fish Allergy
- Author
-
Zuidmeer-Jongejan, L., Huber, H., Swoboda, I., Rigby, N., Versteeg, S.A., Jensen, B.M., Quaak, S., Akkerdaas, J.H., Blom, L., Asturias, J., Bindslev-Jensen, C., Bernardi, M.L., Clausen, M., Ferrara, R., Hauer, M., Heyse, J., Kopp, S., Kowalski, M.L., Lewandowska-Polak, A., Linhart, B., Maderegger, B., Maillere, B., Mari, A., Martinez, A., Mills E.N.C., Neubauer, A., Nicoletti, C., Papadopoulos, N.G., Portoles, A., Ranta-Panula, V., Santos-Magadan, S., Schnoor, H.J., Sigurdardottir, S.T., Stahl-Skov, P., Stavroulakis, G., Stegfellner, G., Vázquez-Cortés, S., Witten, M., Stolz, F., Poulsen, L.K., Fernandez-Rivas, M., Valenta, R., and Van Ree, R.
- Subjects
3. Good health - Abstract
Background: The FAST (food allergy-specific immunotherapy) project aims at developing safe and effective subcutaneous immunotherapy for fish allergy, using recombinant hypoallergenic carp parvalbumin, Cyp c 1. Objectives: Preclinical characterization and good manufacturing practice (GMP) production of mutant Cyp (mCyp) c 1. Methods:Escherichia coli-produced mCyp c 1 was purified using standard chromatographic techniques. Physicochemical properties were investigated by gel electrophoresis, size exclusion chromatography, circular dichroism spectroscopy, reverse-phase high-performance liquid chromatography and mass spectrometry. Allergenicity was assessed by ImmunoCAP inhibition and basophil histamine release assay, immunogenicity by immunization of laboratory animals and stimulation of patients' peripheral blood mononuclear cells (PBMCs). Reference molecules were purified wild-type Cyp c 1 (natural and/or recombinant). GMP-compliant alum-adsorbed mCyp c 1 was tested for acute toxicity in mice and rabbits and for repeated-dose toxicity in mice. Accelerated and real-time protocols were used to evaluate stability of mCyp c 1 as drug substance and drug product. Results: Purified mCyp c 1 behaves as a folded and stable molecule. Using sera of 26 double-blind placebo-controlled food-challenge-proven fish-allergic patients, reduction in allergenic activity ranged from 10- to 5,000-fold (1,000-fold on average), but with retained immunogenicity (immunization in mice/rabbits) and potency to stimulate human PBMCs. Toxicity studies revealed no toxic effects and real-time stability studies on the Al(OH)3-adsorbed drug product demonstrated at least 20 months of stability. Conclusion: The GMP drug product developed for treatment of fish allergy has the characteristics targeted for in FAST: i.e. hypoallergenicity with retained immunogenicity. These results have warranted first-in-man immunotherapy studies to evaluate the safety of this innovative vaccine.
- Published
- 2017
- Full Text
- View/download PDF
165. A multi-center ring trial of allergen analysis using fluorescent multiplex array technology
- Author
-
King, E.M., Filep, S., Smith, B., Platts-Mills, T., Hamilton, R.G., Schmechel, D., Sordillo, J.E., Milton, D., van Ree, R., Krop, E.J.M., Heederik, D.J.J., Metwali, N., Thorne, P.S., Zeldin, D.C., Sever, M.L., Calatroni, A., Arbes, S.J., Mitchell, H.E., Chapman, M.D., Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, and Experimental Immunology
- Subjects
Immunology ,Coronacrisis-Taverne ,Cockroaches ,medicine.disease_cause ,Sensitivity and Specificity ,Article ,Fluorescence ,Mice ,Allergen measurement ,Multiplex array ,Dogs ,Allergen ,immune system diseases ,Hypersensitivity ,medicine ,Animals ,Immunology and Allergy ,Multiplex ,Indoor air quality ,Reference standards ,Immunoassay ,Mites ,Reproducibility ,Occupational health ,medicine.diagnostic_test ,business.industry ,Reproducibility of Results ,Environmental Exposure ,Environmental exposure ,Allergens ,Reference Standards ,Microarray Analysis ,United States ,Asthma ,Rats ,respiratory tract diseases ,Europe ,Multicenter study ,Air Pollution, Indoor ,Cats ,Laboratories ,business ,Environmental Monitoring - Abstract
Consistent performance of allergen assays is essential to ensure reproducibility of exposure assessments for investigations of asthma and occupational allergic disease. This study evaluated intra- and inter-laboratory reproducibility of a fluorescent multiplex array, which simultaneously measures eight indoor allergens in a single reaction well. A multi-center study was performed in nine laboratories in the US and Europe to determine the inter-laboratory variability of an 8-plex array for dust mite, cat, dog, rat, mouse and cockroach allergens. Aliquots of 151 dust extract samples were sent to participating centers and analyzed by each laboratory on three separate occasions. Agreement within and between laboratories was calculated by the concordance correlation coefficient (CCC). Results were obtained for over 32,000 individual allergen measurements. Levels covered a wide range for all allergens from below the lower limit of detection (LLOD = 0.1-9.8 ng/ml) to higher than 6800 ng/ml for all allergens except Mus m 1, which was up to 1700 ng/ml. Results were reproducible within as well as between laboratories. Within laboratories, 94% of CCC were ≥ 0.90, and 80% of intra-laboratory results fell within a 10% coefficient of variance (CV%). Results between laboratories also showed highly significant positive correlations for all allergens (~0.95, p
- Published
- 2013
- Full Text
- View/download PDF
166. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies
- Author
-
Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., Bousquet, J., Clinicum, and Department of Dermatology, Allergology and Venereology
- Subjects
EIP on AHA ,EAACI POSITION PAPER ,RUSH IMMUNOTHERAPY ,GRASS-POLLEN ALLERGY ,INTERNATIONAL CONSENSUS ,EUROPEAN INNOVATION PARTNERSHIP ,NATIONAL DATABASES ,ORAL IMMUNOTHERAPY ,Asthma ,Ageing ,AIRWAYS ICPs ,SUBLINGUAL IMMUNOTHERAPY ,PRECISION MEDICINE ,IMMUNOLOGY/PRACTALL CONSENSUS REPORT ,3121 General medicine, internal medicine and other clinical medicine ,Allergen immunotherapy ,Rhinitis - Abstract
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
- Published
- 2016
167. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project
- Author
-
Bonertz, A., primary, Roberts, G., additional, Slater, J. E., additional, Bridgewater, J., additional, Rabin, R. L., additional, Hoefnagel, M., additional, Timon, M., additional, Pini, C., additional, Pfaar, O., additional, Sheikh, A., additional, Ryan, D., additional, Akdis, C., additional, Goldstein, J., additional, Poulsen, L. K., additional, van Ree, R., additional, Rhyner, C., additional, Barber, D., additional, Palomares, O., additional, Pawankar, R., additional, Hamerlijnk, D., additional, Klimek, L., additional, Agache, I., additional, Angier, E., additional, Casale, T., additional, Fernandez‐Rivas, M., additional, Halken, S., additional, Jutel, M., additional, Lau, S., additional, Pajno, G., additional, Sturm, G., additional, Varga, E. M., additional, Gerth van Wijk, R., additional, Bonini, S., additional, Muraro, A., additional, and Vieths, S., additional
- Published
- 2018
- Full Text
- View/download PDF
168. Identification of a 62-kDa major allergen from Artemisia pollen as a putative galactose oxidase
- Author
-
Fu, W., primary, Gao, Z., additional, Gao, L., additional, Jin, J., additional, Liu, M., additional, Sun, Y., additional, Wu, S., additional, Wu, L., additional, Ma, H., additional, Dong, Y., additional, Wang, X., additional, Gao, B., additional, Wang, H., additional, Akkerdaas, J. H., additional, Versteeg, S. A., additional, and van Ree, R., additional
- Published
- 2018
- Full Text
- View/download PDF
169. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies
- Author
-
Calderon, M.A. Demoly, P. Casale, T. Akdis, C.A. Bachert, C. Bewick, M. Bilò, B.M. Bohle, B. Bonini, S. Bush, A. Caimmi, D.P. Canonica, G.W. Cardona, V. Chiriac, A.M. Cox, L. Custovic, A. De Blay, F. Devillier, P. Didier, A. Di Lorenzo, G. Du Toit, G. Durham, S.R. Eng, P. Fiocchi, A. Fox, A.T. Van Wijk, R.G. Gomez, R.M. Haathela, T. Halken, S. Hellings, P.W. Jacobsen, L. Just, J. Tanno, L.K. Kleine-Tebbe, J. Klimek, L. Knol, E.F. Kuna, P. Larenas-Linnemann, D.E. Linneberg, A. Matricardi, M. Malling, H.J. Moesges, R. Mullol, J. Muraro, A. Papadopoulos, N. Passalacqua, G. Pastorello, E. Pfaar, O. Price, D. Del Rio, P.R. Ruëff, R. Samolinski, B. Scadding, G.K. Senti, G. Shamji, M.H. Sheikh, A. Sisul, J.C. Sole, D. Sturm, G.J. Tabar, A. Van Ree, R. Ventura, M.T. Vidal, C. Varga, E.M. Worm, M. Zuberbier, T. Bousquet, J.
- Abstract
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. © 2016 The Author(s).
- Published
- 2016
170. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies
- Author
-
Calderon, MA, Demoly, P, Casale, T, Akdis, CA, Bachert, C, Bewick, M, Bilo, BM, Bohle, B, Bonini, S, Bush, A, Caimmi, DP, Canonica, GW, Cardona, V, Chiriac, AM, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, SR, Eng, P, Fiocchi, A, Fox, AT, Van Wijk, RG, Gomez, RM, Haathela, T, Halken, S, Hellings, PW, Jacobsen, L, Just, J, Tanno, LK, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, DE, Linneberg, A, Matricardi, M, Malling, HJ, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Rodriguez del Rio, P, Rueff, R, Samolinski, B, Scadding, GK, Senti, G, Shamji, MH, Sheikh, A, Sisul, JC, Sole, D, Sturm, GJ, Tabar, A, Van Ree, R, Ventura, MT, Vidal, C, Varga, EM, Worm, M, Zuberbier, T, Bousquet, J, Internal Medicine, and Medical Research Council (MRC)
- Subjects
Pulmonary and Respiratory Medicine ,EIP on AHA ,Science & Technology ,EAACI POSITION PAPER ,RUSH IMMUNOTHERAPY ,Allergy ,GRASS-POLLEN ALLERGY ,INTERNATIONAL CONSENSUS ,EUROPEAN INNOVATION PARTNERSHIP ,Immunology ,NATIONAL DATABASES ,ORAL IMMUNOTHERAPY ,Ageing ,AIRWAYS ICPs ,Allergen immunotherapy ,Asthma ,Rhinitis ,Immunology and Allergy ,SUBLINGUAL IMMUNOTHERAPY ,PRECISION MEDICINE ,IMMUNOLOGY/PRACTALL CONSENSUS REPORT ,Medicine and Health Sciences ,Life Sciences & Biomedicine - Abstract
European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, European Structural and Development Funds of Region Languedoc Roussillon Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp NHS, London, England UPMC Paris 06, Sorbonne Univ,Dept Pneumol & Addictol,UMR S 1136, Hop Arnaud de Villeneuve,CHRU Montpellier, IPLESP,Equipe EPAR,Unite Allergol, F-75013 Paris, France Univ S Florida, Morsani Coll Med, Tampa, FL USA Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland Univ Hosp Ghent, ENT Dept, Upper Airways Res Lab URL, Ghent, Belgium IQ4U Consultants Ltd, London, England Osped Riuniti, Univ Hosp, Allergy Unit, Dept Internal Med, Ancona, Italy Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria Univ Naples 2, Rome, Italy CNR, IFT, Rome, Italy Univ Genoa, Allergy & Resp Dis Clin, DIMI, IRCCS AOU San Martino IST, Genoa, Italy Hosp Univ Vall dHebron, Allergy Sect, Dept Internal Med, Barcelona, Spain Montpellier UPMC Univ Paris 06, Sorbonne Univ,UMRS 1136, Hop Arnaud de Villeneuve,Equipe EPAR IPLESP, Div Allergy,Dept Pulmonol,Univ Hosp Montpellier, Paris, France Nova Southeastern Univ, Ft Lauderdale, FL USA Univ Hosp Strasbourg, Div Allergy, Chest Dis Dept, Strasbourg, France Univ Versailles St Quentin, Suresnes, France Foch Hosp, Dept Airway Dis, Clin Pharmacol Unit, UPRES EA 220, Suresnes, France Rangueil Larrey Hosp, Dept Resp Dis, Toulouse, France Univ Palermo, Di Bi MIS, Palermo, Italy Kings Coll London, Guys & St Thomas NHS Trust, London, England Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England Childrens Hosp, Dept Pediat Pulmonol & Allergy, Aarau, Switzerland Bambino Gesu Pediat Hosp, Dept Pediat, Div Allergy, Rome, Italy Kings Coll London, Allergy Acad, London, England Erasmus MC, Dept Internal Med, Bldg Rochussenstr, Rotterdam, Netherlands Hosp San Bernardo, Unidad Alergia & Asma, Salta, Argentina Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland Odense Univ Hosp, Hans Christian Andersen Childrens Hosp, Odense, Denmark Katholieke Univ Leuven, Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Louvain, Belgium Secretary Immunotherapy Interest Grp EAACI, Allergy Learning & Consulting, Copenhagen, Denmark UPMC Univ Paris, Sorbonne Univ,Hop Enfants Armand Trousseau,INSERM, Inst Pierre Louis Epidemiol & Sante Publ,Equipe E, Allergol Dept,Ctr Asthme & Allergies,UMR S 1136, Paris, France Hosp Sirio Libanes, Sao Paulo, Brazil Univ Hosp Montpellier, Montpellier, France UPMC Paris 06, Sorbonne Univ, Equipe EPAR, UMR S 1136,IPLESP, Paris, France Ackermann Hanf & Kleine Tebbe, Outpatient Clin & Clin Res Ctr, Allergy & Asthma Ctr Westend, Berlin, Germany German Soc Otorhinolaryngol HNS, Ctr Rhinol & Allergol, Wiesbaden, Germany Univ Med Ctr Utrecht, Dept Immunol & Dermatol Allergol, Utrecht, Netherlands Med Univ Lodz, Lodz, Poland ARIA, Mexico City, DF, Mexico Hosp Med Sur, AAAAI, Mexico City, DF, Mexico Capital Reg Denmark, Res Ctr Prevent & Hlth, Copenhagen, Denmark Rigshosp, Dept Clin Expt Res, Copenhagen, Denmark Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark Charite Med Univ, Pediat Pneumol & Immunol, Berlin, Germany Gentofte Univ Hosp, Allergy Clin, Danish Allergy Ctr, Hellerup, Denmark Klinikum Univ Koln AoR, IMSIE, Cologne, Germany Hosp Clin Barcelona, Unitat Rinol & Clin Olfacte, ENT Dept, Clin & Expt Resp Immunoallergy,IDIBAPS,CIBERES, Barcelona, Catalonia, Spain Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy Univ Athens, Allergy Unit, Pediat Clin 2, Athens, Greece Univ Genoa, Allergy & Resp Dis, IRCCS San Martino IST, Genoa, Italy ASST Grande Osped Metropolitano Niguarda, Pzza Osped Maggiore, Milan, Italy Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany Heidelberg Univ, Med Fac Mannheim, Heidelberg, Germany Ctr Rhinol & Allergol, Wiesbaden, Germany Univ Aberdeen, Acad Primary Care, Div Appl Hlth Sci, Primary Care Resp Med, Aberdeen, Scotland RiRL, Cambridge, England Optimum Patient Care Ltd, Singapore, Singapore Hosp Infantil Univ Nino Jesus, Allergy Sect, Madrid, Spain Ludwig Maximillian Univ, Dept Dermatol & Allergol, Munich, Germany Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland Royal Natl Throat Nose & Ear Hosp, London, England UCL, London, England Univ Zurich Hosp, Clin Trials Ctr, Zurich, Switzerland Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Inflammat Repair & Dev Sec, Immunomodulat & Tolerance Grp,Fac Med, London, England MRC, London, England Asthma UK Ctr Allerg Mechanisms Asthma, London, England Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Asthma UK Ctr Appl Res, Med Informat Ctr, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland SLAAI, Asuncion, Paraguay Univ Fed Sao Paulo, Programa Posgrad Pediat & Ciencias Aplicadas Pedi, Dept Pediat EPM, Sao Paulo, Brazil Med Univ Graz, Dept Dermatol & Venerol, Graz, Austria Allergy Outpatient Clin Reumannplatz, Vienna, Austria Complejo Hosp Navarra, Serv Alergol, Pamplona, Spain Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Interdisciplinary Dept Med, Bari, Italy Complejo Hosp Univ Santiago de Compostela, Dept Allergy, Santiago De Compostela, Spain Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria Charite Univ Med Berlin, Klin Dermatol Venerol & Allergol, Allergie Ctr Charite, Berlin, Germany European Innovat Partnership Act & Hlth Ageing Re, MAlad Chron Vleillissement Actif Languedoc Roussi, Paris, France INSERM, VIMA, Epidemiol & Publ Hlth Approaches, U1168,Ageing & Chron Dis, Paris, France Univ Versailles St Quentin En Yvelines, UVSQ, UMR S 1168, Versailles, France CHRU, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France Programa de Pòs‑Graduação em Pediatria e Ciências Aplicadas à Pediatria, Departamento de Pediatria EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil Web of Science
- Published
- 2016
- Full Text
- View/download PDF
171. Allergen immunotherapy for IgE-mediated food allergy: Protocol for a systematic review
- Author
-
Dhami, S. Nurmatov, U. Pajno, G.B. Fernandez-Rivas, M. Muraro, A. Roberts, G. Akdis, C. Alvaro-Lozano, M. Beyer, K. Bindslev-Jensen, C. Burks, W. Du Toit, G. Ebisawa, M. Eigenmann, P. Knol, E. Makela, M. Nadeau, K.C. O'Mahony, L. Papadopoulos, N. Poulsen, L. Sackesen, C. Sampson, H. Santos, A. Van Ree, R. Timmermans, F. Sheikh, A.
- Abstract
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for IgE-mediated food allergy. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in IgE-mediated food allergy. Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised. Discussion: The findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT. © 2016 Dhami et al.
- Published
- 2016
172. EAACI molecular allergology user's guide
- Author
-
Matricardi, P.M., Kleine-Tebbe, J., Hoffmann, H.J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R.C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilo, M.B., Blank, S., Bohle, B., Bosshard, P.P., Breiteneder, H., Brough, H.A., Caraballo, L.R., Caubet, J.C., Crameri, R., Davies, J.M., Douladiris, N., Ebisawa, M., EIgenmann, P.A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R.G., Hawranek, T., Hellings, P.W., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S.D., Knol, E.F., Korosec, P., Kuehn, A., Lack, G., Lopata, A.L., Makela, M.J., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A.H., Papadopoulos, N.G., Pastorello, E.A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L.K., Raulf, M., Sastre, J., Scala, E., Schmid, J.M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.
- Subjects
Ige ,Ige Cross-reactivity ,Allergy ,Allergy Diagnosis ,Anaphylaxis ,Asthma ,Atopic Dermatitis ,Component-resolved Diagnosis ,Diagnosis ,Diagnostic Algorithms ,Food Allergy ,Guidelines ,Lipocalins ,Microarray ,Molecular Allergology ,Non-spec ,food and beverages - Abstract
The availability of allergen molecules ('components') from several protein families has advanced our understanding of immunoglobulin E (IgE)-mediated responses and enabled 'component-resolved diagnosis' (CRD). The European Academy of Allergy and Clinical Immunology (EAACI) Molecular Allergology User's Guide (MAUG) provides comprehensive information on important allergens and describes the diagnostic options using CRD. Part A of the EAACI MAUG introduces allergen molecules, families, composition of extracts, databases, and diagnostic IgE, skin, and basophil tests. Singleplex and multiplex IgE assays with components improve both sensitivity for low-abundance allergens and analytical specificity; IgE to individual allergens can yield information on clinical risks and distinguish cross-reactivity from true primary sensitization. Part B discusses the clinical and molecular aspects of IgE-mediated allergies to foods (including nuts, seeds, legumes, fruits, vegetables, cereal grains, milk, egg, meat, fish, and shellfish), inhalants (pollen, mold spores, mites, and animal dander), and Hymenoptera venom. Diagnostic algorithms and short case histories provide useful information for the clinical workup of allergic individuals targeted for CRD. Part C covers protein families containing ubiquitous, highly cross-reactive panallergens from plant (lipid transfer proteins, polcalcins, PR-10, profilins) and animal sources (lipocalins, parvalbumins, serum albumins, tropomyosins) and explains their diagnostic and clinical utility. Part D lists 100 important allergen molecules. In conclusion, IgE-mediated reactions and allergic diseases, including allergic rhinoconjunctivitis, asthma, food reactions, and insect sting reactions, are discussed from a novel molecular perspective. The EAACI MAUG documents the rapid progression of molecular allergology from basic research to its integration into clinical practice, a quantum leap in the management of allergic patients.
- Published
- 2016
173. EAACI Molecular Allergology User's Guide
- Author
-
Matricardi, P.M. Kleine-Tebbe, J. Hoffmann, H.J. Valenta, R. Hilger, C. Hofmaier, S. Aalberse, R.C. Agache, I. Asero, R. Ballmer-Weber, B. Barber, D. Beyer, K. Biedermann, T. Bilò, M.B. Blank, S. Bohle, B. Bosshard, P.P. Breiteneder, H. Brough, H.A. Caraballo, L. Caubet, J.C. Crameri, R. Davies, J.M. Douladiris, N. Ebisawa, M. EIgenmann, P.A. Fernandez-Rivas, M. Ferreira, F. Gadermaier, G. Glatz, M. Hamilton, R.G. Hawranek, T. Hellings, P. Hoffmann-Sommergruber, K. Jakob, T. Jappe, U. Jutel, M. Kamath, S.D. Knol, E.F. Korosec, P. Kuehn, A. Lack, G. Lopata, A.L. Mäkelä, M. Morisset, M. Niederberger, V. Nowak-Węgrzyn, A.H. Papadopoulos, N.G. Pastorello, E.A. Pauli, G. Platts-Mills, T. Posa, D. Poulsen, L.K. Raulf, M. Sastre, J. Scala, E. Schmid, J.M. Schmid-Grendelmeier, P. van Hage, M. van Ree, R. Vieths, S. Weber, R. Wickman, M. Muraro, A. Ollert, M.
- Subjects
food and beverages - Abstract
The availability of allergen molecules (‘components’) from several protein families has advanced our understanding of immunoglobulin E (IgE)-mediated responses and enabled ‘component-resolved diagnosis’ (CRD). The European Academy of Allergy and Clinical Immunology (EAACI) Molecular Allergology User's Guide (MAUG) provides comprehensive information on important allergens and describes the diagnostic options using CRD. Part A of the EAACI MAUG introduces allergen molecules, families, composition of extracts, databases, and diagnostic IgE, skin, and basophil tests. Singleplex and multiplex IgE assays with components improve both sensitivity for low-abundance allergens and analytical specificity; IgE to individual allergens can yield information on clinical risks and distinguish cross-reactivity from true primary sensitization. Part B discusses the clinical and molecular aspects of IgE-mediated allergies to foods (including nuts, seeds, legumes, fruits, vegetables, cereal grains, milk, egg, meat, fish, and shellfish), inhalants (pollen, mold spores, mites, and animal dander), and Hymenoptera venom. Diagnostic algorithms and short case histories provide useful information for the clinical workup of allergic individuals targeted for CRD. Part C covers protein families containing ubiquitous, highly cross-reactive panallergens from plant (lipid transfer proteins, polcalcins, PR-10, profilins) and animal sources (lipocalins, parvalbumins, serum albumins, tropomyosins) and explains their diagnostic and clinical utility. Part D lists 100 important allergen molecules. In conclusion, IgE-mediated reactions and allergic diseases, including allergic rhinoconjunctivitis, asthma, food reactions, and insect sting reactions, are discussed from a novel molecular perspective. The EAACI MAUG documents the rapid progression of molecular allergology from basic research to its integration into clinical practice, a quantum leap in the management of allergic patients. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
- Published
- 2016
174. Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy
- Author
-
Ryan, D., primary, Gerth van Wijk, R., additional, Angier, E., additional, Kristiansen, M., additional, Zaman, H., additional, Sheikh, A., additional, Cardona, V., additional, Vidal, C., additional, Warner, A., additional, Agache, I., additional, Arasi, S., additional, Fernandez‐Rivas, M., additional, Halken, S., additional, Jutel, M., additional, Lau, S., additional, Pajno, G., additional, Pfaar, O., additional, Roberts, G., additional, Sturm, G., additional, Varga, E. M., additional, Van Ree, R., additional, and Muraro, A., additional
- Published
- 2017
- Full Text
- View/download PDF
175. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy
- Author
-
Sturm, G. J., primary, Varga, E.‐M., additional, Roberts, G., additional, Mosbech, H., additional, Bilò, M. B., additional, Akdis, C. A., additional, Antolín‐Amérigo, D., additional, Cichocka‐Jarosz, E., additional, Gawlik, R., additional, Jakob, T., additional, Kosnik, M., additional, Lange, J., additional, Mingomataj, E., additional, Mitsias, D. I., additional, Ollert, M., additional, Oude Elberink, J. N. G., additional, Pfaar, O., additional, Pitsios, C., additional, Pravettoni, V., additional, Ruëff, F., additional, Sin, B. A., additional, Agache, I., additional, Angier, E., additional, Arasi, S., additional, Calderón, M. A., additional, Fernandez‐Rivas, M., additional, Halken, S., additional, Jutel, M., additional, Lau, S., additional, Pajno, G. B., additional, van Ree, R., additional, Ryan, D., additional, Spranger, O., additional, van Wijk, R. G., additional, Dhami, S., additional, Zaman, H., additional, Sheikh, A., additional, and Muraro, A., additional
- Published
- 2017
- Full Text
- View/download PDF
176. Debates in allergy, regarding the symposium on: “Position Statements and Therapeutic Guidelines”
- Author
-
Rodríguez del Río, P., primary, Cisteró-Bahima, A., additional, and van Ree, R., additional
- Published
- 2017
- Full Text
- View/download PDF
177. Component‐resolved diagnosis and beyond: Multivariable regression models to predict severity of hazelnut allergy
- Author
-
Datema, M. R., primary, van Ree, R., additional, Asero, R., additional, Barreales, L., additional, Belohlavkova, S., additional, de Blay, F., additional, Clausen, M., additional, Dubakiene, R., additional, Fernández‐Perez, C., additional, Fritsche, P., additional, Gislason, D., additional, Hoffmann‐Sommergruber, K., additional, Jedrzejczak‐Czechowicz, M., additional, Jongejan, L., additional, Knulst, A. C., additional, Kowalski, M., additional, Kralimarkova, T. Z., additional, Le, T.‐M., additional, Lidholm, J., additional, Papadopoulos, N. G., additional, Popov, T. A., additional, del Prado, N., additional, Purohit, A., additional, Reig, I., additional, Seneviratne, S. L., additional, Sinaniotis, A., additional, Versteeg, S. A., additional, Vieths, S., additional, Zwinderman, A. H., additional, Mills, E. N. C., additional, Fernández‐Rivas, M., additional, and Ballmer‐Weber, B., additional
- Published
- 2017
- Full Text
- View/download PDF
178. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis
- Author
-
Roberts, G., primary, Pfaar, O., additional, Akdis, C. A., additional, Ansotegui, I. J., additional, Durham, S. R., additional, Gerth van Wijk, R., additional, Halken, S., additional, Larenas‐Linnemann, D., additional, Pawankar, R., additional, Pitsios, C., additional, Sheikh, A., additional, Worm, M., additional, Arasi, S., additional, Calderon, M. A., additional, Cingi, C., additional, Dhami, S., additional, Fauquert, J. L., additional, Hamelmann, E., additional, Hellings, P., additional, Jacobsen, L., additional, Knol, E. F., additional, Lin, S. Y., additional, Maggina, P., additional, Mösges, R., additional, Oude Elberink, J. N. G., additional, Pajno, G. B., additional, Pastorello, E. A., additional, Penagos, M., additional, Rotiroti, G., additional, Schmidt‐Weber, C. B., additional, Timmermans, F., additional, Tsilochristou, O., additional, Varga, E.‐M., additional, Wilkinson, J. N., additional, Williams, A., additional, Zhang, L., additional, Agache, I., additional, Angier, E., additional, Fernandez‐Rivas, M., additional, Jutel, M., additional, Lau, S., additional, van Ree, R., additional, Ryan, D., additional, Sturm, G. J., additional, and Muraro, A., additional
- Published
- 2017
- Full Text
- View/download PDF
179. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview
- Author
-
Asaria, M., primary, Dhami, S., additional, van Ree, R., additional, Gerth van Wijk, R., additional, Muraro, A., additional, Roberts, G., additional, and Sheikh, A., additional
- Published
- 2017
- Full Text
- View/download PDF
180. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products
- Author
-
Bonertz, A., primary, Roberts, G. C., additional, Hoefnagel, M., additional, Timon, M., additional, Slater, J. E., additional, Rabin, R. L., additional, Bridgewater, J., additional, Pini, C., additional, Pfaar, O., additional, Akdis, C., additional, Goldstein, J., additional, Poulsen, L. K., additional, van Ree, R., additional, Rhyner, C., additional, Barber, D., additional, Palomares, O., additional, Sheikh, A., additional, Pawankar, R., additional, Hamerlijnk, D., additional, Klimek, L., additional, Agache, I., additional, Angier, E., additional, Casale, T., additional, Fernandez‐Rivas, M., additional, Halken, S., additional, Jutel, M., additional, Lau, S., additional, Pajno, G., additional, Sturm, G., additional, Varga, E. M., additional, Gerth van Wijk, R., additional, Bonini, S., additional, Muraro, A., additional, and Vieths, S., additional
- Published
- 2017
- Full Text
- View/download PDF
181. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis
- Author
-
Nurmatov, U., primary, Dhami, S., additional, Arasi, S., additional, Pajno, G. B., additional, Fernandez-Rivas, M., additional, Muraro, A., additional, Roberts, G., additional, Akdis, C., additional, Alvaro-Lozano, M., additional, Beyer, K., additional, Bindslev-Jensen, C., additional, Burks, W., additional, du Toit, G., additional, Ebisawa, M., additional, Eigenmann, P., additional, Knol, E., additional, Makela, M., additional, Nadeau, K. C., additional, O'Mahony, L., additional, Papadopoulos, N., additional, Poulsen, L. K., additional, Sackesen, C., additional, Sampson, H., additional, Santos, A. F., additional, van Ree, R., additional, Timmermans, F., additional, and Sheikh, A., additional
- Published
- 2017
- Full Text
- View/download PDF
182. Erratum : IgE recognition patterns in peanut allergy are age dependent: Perspectives of the EuroPrevall study (Allergy (2015) 70 (391-406))
- Author
-
Ballmer-Weber, B. K., Lidholm, J., Fernández-Rivas, M., Seneviratne, S., Hanschmann, K. M., Vogel, L., Bures, P., Fritsche, P., Summers, C., Knulst, A. C., Le, T. M., Reig, I., Papadopoulos, N. G., Sinaniotis, A., Belohlavkova, S., Popov, T., Kralimarkova, T., De Blay, F., Purohit, A., Clausen, M., Kowalski, M. L., Asero, R., Dubakiene, R., Barreales, L., Clare Mills, E. N., Van Ree, R., and Vieths, S.
- Subjects
Immunology ,Immunology and Allergy - Published
- 2015
183. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products
- Author
-
Bonertz, A. (A.), Roberts, G., Hoefnagel, M. (M.), Timon, M. (M.), Slater, J.E. (J. E.), Rabin, R.L. (R. L.), Bridgewater, J. (J.), Pini, C. (C.), Pfaar, O. (Oliver), Akdis, C.A., Goldstein, J. (J.), Poulsen, L.K., Van Ree, R., Rhyner, C. (Claudio), Barber, D. (D.), Palomares, O. (O.), Sheikh, A. (Aziz), Pawankar, R. (Ruby), Hamerlijnk, D. (D.), Klimek, L. (Ludger), Agache, I., Angier, E. (E.), Casale, T.B. (Thomas), Fernandez Rivas, M. (M.), Halken, S. (Susanne), Jutel, M. (M.), Lau, S. (Susanne), Pajno, G. (G.), Sturm, G.J., Varga, E.M., Gerth van Wijk, R. (R.), Bonini, S. (Sergio), Muraro, A. (A.), Vieths, S. (S.), Bonertz, A. (A.), Roberts, G., Hoefnagel, M. (M.), Timon, M. (M.), Slater, J.E. (J. E.), Rabin, R.L. (R. L.), Bridgewater, J. (J.), Pini, C. (C.), Pfaar, O. (Oliver), Akdis, C.A., Goldstein, J. (J.), Poulsen, L.K., Van Ree, R., Rhyner, C. (Claudio), Barber, D. (D.), Palomares, O. (O.), Sheikh, A. (Aziz), Pawankar, R. (Ruby), Hamerlijnk, D. (D.), Klimek, L. (Ludger), Agache, I., Angier, E. (E.), Casale, T.B. (Thomas), Fernandez Rivas, M. (M.), Halken, S. (Susanne), Jutel, M. (M.), Lau, S. (Susanne), Pajno, G. (G.), Sturm, G.J., Varga, E.M., Gerth van Wijk, R. (R.), Bonini, S. (Sergio), Muraro, A. (A.), and Vieths, S. (S.)
- Abstract
Regulatory approaches for allergen immunotherapy (AIT) products and the availability of high-quality AIT products are inherently linked to each other. While allergen products are available in many countries across the globe, their regulation is very heterogeneous. First, we describe the regulatory systems applicable for AIT products in the European Union (EU) and in the United States (US). For Europe, a depiction of the different types of relevant procedures, as well as the committees involved, is provided and the fundamental role of national agencies of the EU member states in this complex and unique network is highlighted. Furthermore, the regulatory agencies from Australia, Canada, Japan, Russia, and Switzerland provided information on the system implemented in their countries for the regulation of allergen products. While AIT products are commonly classified as biological
- Published
- 2017
- Full Text
- View/download PDF
184. Abstracts from the Food Allergy and Anaphylaxis Meeting 2016
- Author
-
Pouessel, G, Claverie, C, Labreuche, J, Renaudin, J-M, Dorkenoo, A, Eb, M, Moneret-Vautrin, A, Deschildre, A, Leteurtre, S, Grabenhenrich, L, Worm, M, Dölle, S, Scherer, K, Hutteger, I, Christensen, M, Bindslev-Jensen, C, Mortz, C, Eller, E, Kjaer, HF, Carneiro-Leão, L, Badas, J, Coimbra, A, Levy, DP, Ben-Shoshan, M, Rimon, A, Benor, S, Arends, NJT, Edelbroek, N, de Groot, H, Emons, JAM, Brand, HKA, Verhoeven, D, van Veen, LN, de Jong, NW, Noh, G, Jang, EH, Pascal, M, Dominguez, O, Piquer, M, Alvaro, M, Jimenez-Feijoo, R, Lozano, J, Machinena, A, del Mar Folqué, M, Giner, MT, Plaza, AM, Turner, P, Patel, N, Vazquez-Ortiz, M, Lindsley, S, Walker, L, Rosenberg, S, Mari, A, Alessandri, C, Giangrieco, I, Tuppo, L, Rafaiani, C, Mitterer, G, Ciancamerla, M, Ferrara, R, Bernardi, ML, Zennaro, D, Tamburrini, M, Ciardiello, MA, Harwanegg, C, Fernandez, A, Selb, R, Egenmann, P, Epstein, M, Hoffmann-Sommergruber, K, Koning, F, Lovik, M, Clare Mills, EN, Moreno, J, van Loveren, H, Wal, J-M, Diesner, S, Bergmayr, C, Pfitzner, B, Assmann, VE, Starkl, P, Endesfelder, D, Eiwegger, T, Szepfalusi, Z, Fehrenbach, H, Jensen-Jarolim, E, Hartmann, A, Pali-Schöll, I, Untersmayr, E, Wille, S, Meyer, P, Klingebiel, C, Lidholm, J, Ehrenberg, A, Östling, J, Cleach, I, Mège, J-L, Vitte, J, Aina, R, Dubiela, P, Pfeifer, S, Bublin, M, Radauer, C, Humeniuk, P, Kabasser, S, Asero, R, Bogas, G, Gomez, F, Campo, P, Salas, M, Doña, I, Barrionuevo, E, Guerrero, MA, Mayorga, C, Prieto, A, Barber, D, Torres, MJ, Jamin, A, Wangorsch, A, Ballmer, B, Vieths, S, Scheurer, S, Apostolovic, D, Mihailovic, J, Krstic, M, Starkhammar, M, Velickovic, TC, Hamsten, C, van Hage, M, van Erp, FC, Knol, EF, Kansen, HM, Pontoppidan, B, Meijer, Y, van der Ent, CK, Knulst, AC, Sayers, R, Brown, H, Custovic, A, Simpson, A, Mills, C, Schulz, J, Akkerdaas, J, Totis, M, Capt, A, Herouet-Guicheney, C, van Ree, R, Banerjee, T, Banerjee, A, Claude, M, Bouchaud, G, Lupi, R, Castan, L, Tranquet, O, Denery-Papini, S, Bodinier, M, Brossard, C, De Poi, R, Gritti, E, De Dominicis, E, Popping, B, de Laureto, PP, Palosuo, K, Kukkonen, AK, Pelkonen, A, Mäkelä, M, Lee, NA, Rost, J, Muralidharan, S, Campbell, D, Mehr, S, Nock, C, Baumert, J, Taylor, S, Mastrorilli, C, Tripodi, S, Caffarelli, C, Perna, S, Di Rienzo Businco, A, Sfika, I, Dondi, A, Bianchi, A, Dascola, CP, Ricci, G, Cipriani, F, Maiello, N, del Giudice, MM, Frediani, T, Frediani, S, Macrì, F, Pistoletti, C, Iacono, ID, Patria, MF, Varin, E, Peroni, D, Comberiati, P, Chini, L, Moschese, V, Lucarelli, S, Bernardini, R, Pingitore, G, Pelosi, U, Olcese, R, Moretti, M, Cirisano, A, Faggian, D, Travaglini, A, Plebani, M, Verga, MC, Calvani, M, Giordani, P, Matricardi, PM, Ontiveros, N, Cabrera-Chavez, F, Galand, J, Beaudouin, E, Pineau, F, Sakai, S, Matsunaga, K, Teshima, R, Larré, C, Denery, S, Tschirner, S, Trendelenburg, V, Schulz, G, Niggemann, B, Beyer, K, Bouferkas, Y, Belabbas, Y, Saidi, D, Kheroua, O, Mecherfi, KEE, Guendouz, M, Haddi, A, Kaddouri, H, Amaral, L, Pereira, A, Rodrigues, S, Datema, M, Jongejan, L, Clausen, M, Knulst, A, Papadopoulos, N, Kowalski, M, de Blay, F, Zwinderman, A, Hoffman-Sommergruber, K, Ballmer-Weber, B, Fernandez-Rivas, M, Deng, S, Yin, J, Eisenmann, C, Nassiri, M, Reinert, R, van der Valk, JPM, van Wijk, RG, Vergouwe, Y, Steyerberg, EW, Reitsma, M, Wichers, HJ, Savelkoul, HFJ, Vlieg-Boerstra, B, Dubois, AEJ, Carolino, F, Rodolfo, A, Cernadas, J, Roa-Medellín, D, Rodriguez-Fernandez, A, Navarro, J, Albendiz, V, Baeza, ML, Intente-Herrero, S, Mikkelsen, A, Mehlig, K, Lissner, L, Verrill, L, Luccioli, S, van Bilsen, J, Kuper, F, Wolterbeek, A, Rankouhi, TR, Verschuren, L, Cnossen, H, Jeurink, P, Garssen, J, Knippels, L, Garthoff, J, Houben, G, Leeman, W, Eleonore Pettersson, M, Schins, AMM, Koppelman, GH, Kollen, BJ, Zubchenko, S, Kuntz, S, Mérida, P, Álvaro, M, Riggioni, C, Castellanos, JH, Jimenez, R, Cap, M, Drumez, E, Lejeune, S, Thumerelle, C, Mordacq, C, Nève, V, Ricò, S, Varini, M, Nocerino, R, Cosenza, L, Amoroso, A, Di Costanzo, M, Di Scala, C, Bedogni, G, Canani, RB, Turner, PJ, Poza-Guedes, P, González-Pérez, R, Sánchez-Machín, I, Matheu-Delgado, V, Wambre, E, Ballegaard, A-S, Madsen, C, Gregersen, J, Bøgh, KL, Aubert, P, Neunlist, M, Magnan, A, Lozano-Ojalvo, D, Pablos-Tanarro, A, Pérez-Rodríguez, L, Molina, E, López-Fandiño, R, Rekima, A, Macchiaverni, P, Turfkruyer, M, Holvoet, S, Dupuis, L, Baiz, N, Annesi-Maesano, I, Mercenier, A, Nutten, S, Verhasselt, V, Mrakovcic-Sutic, I, Banac, S, Sutic, I, Baricev-Novakovic, Z, Pavisic, V, Muñoz-Cano, R, Jiménez-Rodríguez, T, Corbacho, D, Roca-Ferrer, J, Bartra, J, Bulog, A, Micovic, V, Markiewicz, L, Szymkiewicz, A, Szyc, A, Wróblewska, B, Harvey, BM, Harthoorn, LF, Wesley Burks, A, Rentzos, G, Björk, A-LB, Bengtsson, U, Barber, C, Kalicinsky, C, Breynaert, C, Coorevits, L, Jansen, C, Van Hoeyveld, E, Verbeke, K, Kochuyt, A-M, Schrijvers, R, Deleanu, D, Muntean, A, Konstantakopoulou, M, Pasioti, M, Papadopoulou, A, Iliopoulou, A, Mikos, N, Kompoti, E, de Castro, ED, Bartalomé, B, Ue, KL, Griffiths, E, Till, S, Grimshaw, K, Roberts, G, Selby, A, Butiene, I, Larco, JI, Dubakiene, R, Fiandor, A, Fiocchi, A, Sigurdardottir, S, Sprikkelman, A, Schoemaker, A-F, Xepapadaki, P, Keil, T, Cojocariu, Z, Barbado, BS, Iancu, V, Arroabarren, E, Esarte, MG, Arteaga, M, Andrade, MC, Borges, D, Kalil, J, Bianchi, PG, Agondi, RC, Gupta, RK, Sharma, A, Gupta, K, Das, M, Dwivedi, P, Karseladze, R, Jorjoliani, L, Saginadze, L, Tskhakaia, M, Basello, K, Piuri, G, Speciani, AF, Speciani, MC, Camerotto, C, Zinno, F, Pakholchuk, O, Nedelska, S, Pattini, S, Costantino, MT, Peveri, S, Villalta, D, Savi, E, Costanzi, A, Revyakina, VA, Kiseleva, MA, Kuvshinova, ED, Larkova, IA, Shekhetov, AA, Silva, D, Moreira, A, Plácido, J, van der Kleij, H, van Twuijver, E, Sutorius, R, de Kam, P-J, van Odijk, J, Lindqvist, H, Lustig, E, Jácome, AAA, Aguilar, KLB, Domínguez, MG, Hernández, DAM, Caruso, C, Casale, C, Rapaccini, GL, Romano, A, De Vitis, I, Cocco, RR, Aranda, C, Mallozi, MC, Motta, JF, Moraes, L, Pastorino, A, Rosario, N, Goudouris, E, Porto, A, Wandalsen, NF, Sarinho, E, Sano, F, Solé, D, Pitsios, C, Petrodimopoulou, M, Papadopoulou, E, Passioti, M, Kontogianni, M, Adamia, N, Khaleva, E, del Prado, AP, Du Toit, G, Krzych, E, Samolinska-Zawisza, U, Furmanczyk, K, Tomaszewska, A, Raciborski, F, Lipiec, A, Samel-Kowalik, P, Walkiewicz, A, Borowicz, J, Samolinski, B, Nano, AL, Recto, M, Somoza, ML, López, NB, Alzate, DP, Ruano, FJ, Garcimartín, MI, Haroun, E, de la Torre, MV, Rojas, A, Onieva, ML, Canto, G, Rodrigues, A, Forno, A, Cabral, AJ, Gonçalves, R, Vorozhko, I, Sentsova, T, Chernyak, O, Denisova, S, Ilènko, L, Muhortnich, V, Zimmermann, C, Rohrbach, A, Bakhsh, FR, Boudewijn, K, Oomkes-Pilon, A-M, Van Ginkle, D, Šilar, M, Jeverica, A, Vesel, T, Avčin, T, Korošec, P, van der Valk, J, Berends, I, Arends, N, van Maaren, M, Wichers, H, Emons, J, Dubois, A, de Jong, N, Matsyura, O, Besh, L, Huang, C-H, Jan, T-R, Stiefel, G, Tratt, J, Kirk, K, Arasi, S, Caminiti, L, Crisafulli, G, Fiamingo, C, Fresta, J, Pajno, G, Remington, B, Kruizinga, A, Marty Blom, W, Westerhout, J, Bijlsma, S, Blankestijn, M, Otten, H, Klemans, R, Michelsen-Huisman, AD, van Os-Medendorp, H, Kruizinga, AG, Versluis, A, van Duijn, G, de Zeeuw-Brouwer, HM-L, Castenmiller, JJM, Noteborn, HPJM, Houben, GF, Bravin, K, Luyt, D, Javed, B, Couch, P, Munro, C, Padfield, P, Sperrin, M, Byrne, A, Oosthuizen, L, Kelleher, C, Ward, F, Brosnan, N, King, G, Corbet, E, Guzmán, JAH, García, MB, Asensio, O, Navarrete, LV, Larramona, H, Miró, XD, Pyrz, K, Austin, M, Boloh, Y, Galloway, D, Hernandez, P, Hourihane, JOB, Kenna, F, Majkowska-Wojciechowska, B, Regent, L, Themisb, M, Schnadt, S, Semic-Jusufagic, A, Galvin, AD, Kauppila, T, Kuitunen, M, Kitsioulis, NA, Douladiris, N, Kostoudi, S, Manolaraki, I, Mitsias, D, Manousakis, E, Papadopoulos, NG, Knibb, R, Hammond, J, Cooke, R, Yrjänä, J, Hanni, A-M, Vähäsarja, P, Mustonen, O, Dunder, T, Kulmala, P, Lasa, E, D’Amelio, C, Martínez, S, Joral, A, Gastaminza, G, Goikoetxea, MJ, Candy, DCA, Van Ampting, MTJ, Oude Nijhuis, MM, Butt, AM, Peroni, DG, Fox, AT, Knol, J, Michaelis, LJ, Padua, I, Padrao, P, Moreira, P, Barros, R, Sharif, H, Ahmed, M, Gomaa, N, Mens, J, Smit, K, Timmermans, F, Poredoš, T, Jeverica, AK, Sedmak, M, Benedik, E, Accetto, M, Zupančič, M, Yonamine, G, Soldateli, G, Aquilante, B, Pastorino, AC, de Moraes Beck, CL, Gushken, AK, de Barros Dorna, M, dos Santos, CN, Castro, APM, Al-Qahtani, A, Arnaout, R, Khaliq, AR, Amin, R, Sheikh, F, Alvarez, J, Anda, M, Palacios, M, De Prada, M, Ponce, C, Balbino, B, Sibilano, R, Marichal, T, Gaudenzio, N, Karasuyama, H, Bruhns, P, Tsai, M, Reber, LL, Galli, SJ, Ferreira, AR, Cernadas, JR, del Campo García, A, Fernández, SP, Carrera, NS, Sánchez-Cruz, FB, Lorenzo, JRF, Claus, S, Pföhler, C, Ruëff, F, Treudler, R, Jaume, ME, Madroñero, A, Perez, MTG, Julia, JC, Plovdiv, CH, Gethings, L, Langridge, J, Adel-Patient, K, Bernard, H, Barcievic-Jones, I, Sokolova, R, Yankova, R, Ivanovska, M, Murdjeva, M, Popova, T, Dermendzhiev, S, Karjalainen, M, Lehnigk, U, Brown, D, Locklear, JC, Locklear, J, Maris, I, Hourihane, J, Ornelas, C, Caiado, J, Ferreira, MB, Pereira-Barbosa, M, Puente, Y, Daza, JC, Monteseirin, FJ, Ukleja-Sokolowska, N, Gawronska-Ukleja, E, Zbikowska-Gotz, M, Bartuzi, Z, Sokolowski, L, Adams, A, Mahon, B, English, K, Gourdon-Dubois, N, Sellam, L, Pereira, B, Michaud, E, Messaoudi, K, Evrard, B, Fauquert, J-L, Palomares, F, Gomez, G, Rodriguez, MJ, Galindo, L, Molina, A, Paparo, L, Mennini, M, Aitoro, R, Wawrzeńczyk, A, Przybyszewski, M, Sarıcoban, HE, Ugras, M, Yalvac, Z, Flokstra-de Blok, BMJ, van der Velde, JL, Vereda, A, Ippolito, C, Traversa, A, Adriano, D, Bianchi, DM, Gallina, S, Decastelli, L, Makatsori, M, Miles, A, Devetak, SP, Devetak, I, Tabet, SA, Trandbohus, JF, Winther, P, Malling, H-J, Hansen, KS, Garvey, LH, Wang, C-C, Cheng, Y-H, Tung, C-W, Dietrich, M, Marenholz, I, Kalb, B, Grosche, S, Blümchen, K, Schlags, R, Price, M, Rietz, S, Esparza-Gordillo, J, Lau, S, Lee, Y-A, Almontasheri, A, Bahkali, MA, Elshorbagi, S, Alfhaid, A, Altamimi, M, Madbouly, E, Al-Dhekri, H, Arnaout, RK, Basagaña, M, Miquel, S, Bartolomé, B, Brix, B, Rohwer, S, Brandhoff, S, Berger, A, Suer, W, Weimann, A, Bueno, C, Martín-Pedraza, L, Abián, S, Segundo-Acosta, PS, López-Rodríguez, JC, Barderas, R, Batanero, E, Cuesta-Herranz, J, Villalba, MT, Correia, M, Benito-Garcia, F, Arêde, C, Piedade, S, Morais-Almeida, M, Hindley, J, Yarham, R, Kuklinska-Pijanka, A, Gillick, D, Patient, K, Chapman, MD, Miranda, A, Matos, E, Sokolova, A, Rao, H, Baricevic-Jones, I, Smith, F, Xue, W, Magnusdottir, H, Vidarsdottir, AG, Lund, S, Jensen, AB, Ludviksson, BR, Simon, R, Elfont, R, Bennett, S, Voyksner, R, de Lurdes Torre, M, Yürek, S, Faber, MA, Bastiaensen, A, Mangodt, E, van Gasse, A, Decuyper, I, Sabato, V, Hagendorens, MM, Bridts, CH, De Clerck, LS, Ebo, D, Schwarz, S, Ziegert, M, Albroscheit, S, Schwager, C, Kull, S, Behrends, J, Röckendorf, N, Schocker, F, Frey, A, Homann, A, Becker, W-M, Jappe, U, Zaabat, N, Osscini, S, Agabriel, C, Sterling, B, Carsin, A, Liabeuf, V, Maćków, M, Zbróg, A, Bronkowska, M, Courtois, J, Gadisseur, R, Bertholet, C, Lukas, P, Cavalier, E, Delahaut, P, Quinting, B, Gertmo, MB, Hasseus, ET, Barzylovych, V, Oliveira, J, Ensina, LF, Aranda, CS, Dopazo, L, Lopez, R, Perez, R, Santos-Diez, L, Bilbao, A, Garcia, JM, Núñez, IG, Mármol, MÁA, Villarejo, MJB, Martos, JAB, Vergara, MS, García, JMI, Michalska, A, Sergiejko, G, Zacniewski, R, Ghiordanescu, I-M, Deaconu, C, Popescu, M, Bumbacea, RS, Ibranji, A, Nikolla, E, Loloci, G, Juel-Berg, N, Larsen, LF, Poulsen, LK, Marcelino, J, Prata, R, Costa, AC, Duarte, F, Neto, M, Santos, J, Pestana, LC, Sampaio, D, Minale, P, Dignetti, P, Bignardi, D, Nedelea, I, Popescu, F-D, Vieru, M, Secureanu, F-A, Ganea, CS, Vieira, M, Silva, JPM, Watts, T, Watts, S, Lomikovska, M, Peredelskaya, M, Nenasheva, N, Filipovic, I, Zivkovic, Z, Filipovic, D, Higgs, J, Warner, A, Jones, C, Pouessel, G, Claverie, C, Labreuche, J, Renaudin, J-M, Dorkenoo, A, Eb, M, Moneret-Vautrin, A, Deschildre, A, Leteurtre, S, Grabenhenrich, L, Worm, M, Dölle, S, Scherer, K, Hutteger, I, Christensen, M, Bindslev-Jensen, C, Mortz, C, Eller, E, Kjaer, HF, Carneiro-Leão, L, Badas, J, Coimbra, A, Levy, DP, Ben-Shoshan, M, Rimon, A, Benor, S, Arends, NJT, Edelbroek, N, de Groot, H, Emons, JAM, Brand, HKA, Verhoeven, D, van Veen, LN, de Jong, NW, Noh, G, Jang, EH, Pascal, M, Dominguez, O, Piquer, M, Alvaro, M, Jimenez-Feijoo, R, Lozano, J, Machinena, A, del Mar Folqué, M, Giner, MT, Plaza, AM, Turner, P, Patel, N, Vazquez-Ortiz, M, Lindsley, S, Walker, L, Rosenberg, S, Mari, A, Alessandri, C, Giangrieco, I, Tuppo, L, Rafaiani, C, Mitterer, G, Ciancamerla, M, Ferrara, R, Bernardi, ML, Zennaro, D, Tamburrini, M, Ciardiello, MA, Harwanegg, C, Fernandez, A, Selb, R, Egenmann, P, Epstein, M, Hoffmann-Sommergruber, K, Koning, F, Lovik, M, Clare Mills, EN, Moreno, J, van Loveren, H, Wal, J-M, Diesner, S, Bergmayr, C, Pfitzner, B, Assmann, VE, Starkl, P, Endesfelder, D, Eiwegger, T, Szepfalusi, Z, Fehrenbach, H, Jensen-Jarolim, E, Hartmann, A, Pali-Schöll, I, Untersmayr, E, Wille, S, Meyer, P, Klingebiel, C, Lidholm, J, Ehrenberg, A, Östling, J, Cleach, I, Mège, J-L, Vitte, J, Aina, R, Dubiela, P, Pfeifer, S, Bublin, M, Radauer, C, Humeniuk, P, Kabasser, S, Asero, R, Bogas, G, Gomez, F, Campo, P, Salas, M, Doña, I, Barrionuevo, E, Guerrero, MA, Mayorga, C, Prieto, A, Barber, D, Torres, MJ, Jamin, A, Wangorsch, A, Ballmer, B, Vieths, S, Scheurer, S, Apostolovic, D, Mihailovic, J, Krstic, M, Starkhammar, M, Velickovic, TC, Hamsten, C, van Hage, M, van Erp, FC, Knol, EF, Kansen, HM, Pontoppidan, B, Meijer, Y, van der Ent, CK, Knulst, AC, Sayers, R, Brown, H, Custovic, A, Simpson, A, Mills, C, Schulz, J, Akkerdaas, J, Totis, M, Capt, A, Herouet-Guicheney, C, van Ree, R, Banerjee, T, Banerjee, A, Claude, M, Bouchaud, G, Lupi, R, Castan, L, Tranquet, O, Denery-Papini, S, Bodinier, M, Brossard, C, De Poi, R, Gritti, E, De Dominicis, E, Popping, B, de Laureto, PP, Palosuo, K, Kukkonen, AK, Pelkonen, A, Mäkelä, M, Lee, NA, Rost, J, Muralidharan, S, Campbell, D, Mehr, S, Nock, C, Baumert, J, Taylor, S, Mastrorilli, C, Tripodi, S, Caffarelli, C, Perna, S, Di Rienzo Businco, A, Sfika, I, Dondi, A, Bianchi, A, Dascola, CP, Ricci, G, Cipriani, F, Maiello, N, del Giudice, MM, Frediani, T, Frediani, S, Macrì, F, Pistoletti, C, Iacono, ID, Patria, MF, Varin, E, Peroni, D, Comberiati, P, Chini, L, Moschese, V, Lucarelli, S, Bernardini, R, Pingitore, G, Pelosi, U, Olcese, R, Moretti, M, Cirisano, A, Faggian, D, Travaglini, A, Plebani, M, Verga, MC, Calvani, M, Giordani, P, Matricardi, PM, Ontiveros, N, Cabrera-Chavez, F, Galand, J, Beaudouin, E, Pineau, F, Sakai, S, Matsunaga, K, Teshima, R, Larré, C, Denery, S, Tschirner, S, Trendelenburg, V, Schulz, G, Niggemann, B, Beyer, K, Bouferkas, Y, Belabbas, Y, Saidi, D, Kheroua, O, Mecherfi, KEE, Guendouz, M, Haddi, A, Kaddouri, H, Amaral, L, Pereira, A, Rodrigues, S, Datema, M, Jongejan, L, Clausen, M, Knulst, A, Papadopoulos, N, Kowalski, M, de Blay, F, Zwinderman, A, Hoffman-Sommergruber, K, Ballmer-Weber, B, Fernandez-Rivas, M, Deng, S, Yin, J, Eisenmann, C, Nassiri, M, Reinert, R, van der Valk, JPM, van Wijk, RG, Vergouwe, Y, Steyerberg, EW, Reitsma, M, Wichers, HJ, Savelkoul, HFJ, Vlieg-Boerstra, B, Dubois, AEJ, Carolino, F, Rodolfo, A, Cernadas, J, Roa-Medellín, D, Rodriguez-Fernandez, A, Navarro, J, Albendiz, V, Baeza, ML, Intente-Herrero, S, Mikkelsen, A, Mehlig, K, Lissner, L, Verrill, L, Luccioli, S, van Bilsen, J, Kuper, F, Wolterbeek, A, Rankouhi, TR, Verschuren, L, Cnossen, H, Jeurink, P, Garssen, J, Knippels, L, Garthoff, J, Houben, G, Leeman, W, Eleonore Pettersson, M, Schins, AMM, Koppelman, GH, Kollen, BJ, Zubchenko, S, Kuntz, S, Mérida, P, Álvaro, M, Riggioni, C, Castellanos, JH, Jimenez, R, Cap, M, Drumez, E, Lejeune, S, Thumerelle, C, Mordacq, C, Nève, V, Ricò, S, Varini, M, Nocerino, R, Cosenza, L, Amoroso, A, Di Costanzo, M, Di Scala, C, Bedogni, G, Canani, RB, Turner, PJ, Poza-Guedes, P, González-Pérez, R, Sánchez-Machín, I, Matheu-Delgado, V, Wambre, E, Ballegaard, A-S, Madsen, C, Gregersen, J, Bøgh, KL, Aubert, P, Neunlist, M, Magnan, A, Lozano-Ojalvo, D, Pablos-Tanarro, A, Pérez-Rodríguez, L, Molina, E, López-Fandiño, R, Rekima, A, Macchiaverni, P, Turfkruyer, M, Holvoet, S, Dupuis, L, Baiz, N, Annesi-Maesano, I, Mercenier, A, Nutten, S, Verhasselt, V, Mrakovcic-Sutic, I, Banac, S, Sutic, I, Baricev-Novakovic, Z, Pavisic, V, Muñoz-Cano, R, Jiménez-Rodríguez, T, Corbacho, D, Roca-Ferrer, J, Bartra, J, Bulog, A, Micovic, V, Markiewicz, L, Szymkiewicz, A, Szyc, A, Wróblewska, B, Harvey, BM, Harthoorn, LF, Wesley Burks, A, Rentzos, G, Björk, A-LB, Bengtsson, U, Barber, C, Kalicinsky, C, Breynaert, C, Coorevits, L, Jansen, C, Van Hoeyveld, E, Verbeke, K, Kochuyt, A-M, Schrijvers, R, Deleanu, D, Muntean, A, Konstantakopoulou, M, Pasioti, M, Papadopoulou, A, Iliopoulou, A, Mikos, N, Kompoti, E, de Castro, ED, Bartalomé, B, Ue, KL, Griffiths, E, Till, S, Grimshaw, K, Roberts, G, Selby, A, Butiene, I, Larco, JI, Dubakiene, R, Fiandor, A, Fiocchi, A, Sigurdardottir, S, Sprikkelman, A, Schoemaker, A-F, Xepapadaki, P, Keil, T, Cojocariu, Z, Barbado, BS, Iancu, V, Arroabarren, E, Esarte, MG, Arteaga, M, Andrade, MC, Borges, D, Kalil, J, Bianchi, PG, Agondi, RC, Gupta, RK, Sharma, A, Gupta, K, Das, M, Dwivedi, P, Karseladze, R, Jorjoliani, L, Saginadze, L, Tskhakaia, M, Basello, K, Piuri, G, Speciani, AF, Speciani, MC, Camerotto, C, Zinno, F, Pakholchuk, O, Nedelska, S, Pattini, S, Costantino, MT, Peveri, S, Villalta, D, Savi, E, Costanzi, A, Revyakina, VA, Kiseleva, MA, Kuvshinova, ED, Larkova, IA, Shekhetov, AA, Silva, D, Moreira, A, Plácido, J, van der Kleij, H, van Twuijver, E, Sutorius, R, de Kam, P-J, van Odijk, J, Lindqvist, H, Lustig, E, Jácome, AAA, Aguilar, KLB, Domínguez, MG, Hernández, DAM, Caruso, C, Casale, C, Rapaccini, GL, Romano, A, De Vitis, I, Cocco, RR, Aranda, C, Mallozi, MC, Motta, JF, Moraes, L, Pastorino, A, Rosario, N, Goudouris, E, Porto, A, Wandalsen, NF, Sarinho, E, Sano, F, Solé, D, Pitsios, C, Petrodimopoulou, M, Papadopoulou, E, Passioti, M, Kontogianni, M, Adamia, N, Khaleva, E, del Prado, AP, Du Toit, G, Krzych, E, Samolinska-Zawisza, U, Furmanczyk, K, Tomaszewska, A, Raciborski, F, Lipiec, A, Samel-Kowalik, P, Walkiewicz, A, Borowicz, J, Samolinski, B, Nano, AL, Recto, M, Somoza, ML, López, NB, Alzate, DP, Ruano, FJ, Garcimartín, MI, Haroun, E, de la Torre, MV, Rojas, A, Onieva, ML, Canto, G, Rodrigues, A, Forno, A, Cabral, AJ, Gonçalves, R, Vorozhko, I, Sentsova, T, Chernyak, O, Denisova, S, Ilènko, L, Muhortnich, V, Zimmermann, C, Rohrbach, A, Bakhsh, FR, Boudewijn, K, Oomkes-Pilon, A-M, Van Ginkle, D, Šilar, M, Jeverica, A, Vesel, T, Avčin, T, Korošec, P, van der Valk, J, Berends, I, Arends, N, van Maaren, M, Wichers, H, Emons, J, Dubois, A, de Jong, N, Matsyura, O, Besh, L, Huang, C-H, Jan, T-R, Stiefel, G, Tratt, J, Kirk, K, Arasi, S, Caminiti, L, Crisafulli, G, Fiamingo, C, Fresta, J, Pajno, G, Remington, B, Kruizinga, A, Marty Blom, W, Westerhout, J, Bijlsma, S, Blankestijn, M, Otten, H, Klemans, R, Michelsen-Huisman, AD, van Os-Medendorp, H, Kruizinga, AG, Versluis, A, van Duijn, G, de Zeeuw-Brouwer, HM-L, Castenmiller, JJM, Noteborn, HPJM, Houben, GF, Bravin, K, Luyt, D, Javed, B, Couch, P, Munro, C, Padfield, P, Sperrin, M, Byrne, A, Oosthuizen, L, Kelleher, C, Ward, F, Brosnan, N, King, G, Corbet, E, Guzmán, JAH, García, MB, Asensio, O, Navarrete, LV, Larramona, H, Miró, XD, Pyrz, K, Austin, M, Boloh, Y, Galloway, D, Hernandez, P, Hourihane, JOB, Kenna, F, Majkowska-Wojciechowska, B, Regent, L, Themisb, M, Schnadt, S, Semic-Jusufagic, A, Galvin, AD, Kauppila, T, Kuitunen, M, Kitsioulis, NA, Douladiris, N, Kostoudi, S, Manolaraki, I, Mitsias, D, Manousakis, E, Papadopoulos, NG, Knibb, R, Hammond, J, Cooke, R, Yrjänä, J, Hanni, A-M, Vähäsarja, P, Mustonen, O, Dunder, T, Kulmala, P, Lasa, E, D’Amelio, C, Martínez, S, Joral, A, Gastaminza, G, Goikoetxea, MJ, Candy, DCA, Van Ampting, MTJ, Oude Nijhuis, MM, Butt, AM, Peroni, DG, Fox, AT, Knol, J, Michaelis, LJ, Padua, I, Padrao, P, Moreira, P, Barros, R, Sharif, H, Ahmed, M, Gomaa, N, Mens, J, Smit, K, Timmermans, F, Poredoš, T, Jeverica, AK, Sedmak, M, Benedik, E, Accetto, M, Zupančič, M, Yonamine, G, Soldateli, G, Aquilante, B, Pastorino, AC, de Moraes Beck, CL, Gushken, AK, de Barros Dorna, M, dos Santos, CN, Castro, APM, Al-Qahtani, A, Arnaout, R, Khaliq, AR, Amin, R, Sheikh, F, Alvarez, J, Anda, M, Palacios, M, De Prada, M, Ponce, C, Balbino, B, Sibilano, R, Marichal, T, Gaudenzio, N, Karasuyama, H, Bruhns, P, Tsai, M, Reber, LL, Galli, SJ, Ferreira, AR, Cernadas, JR, del Campo García, A, Fernández, SP, Carrera, NS, Sánchez-Cruz, FB, Lorenzo, JRF, Claus, S, Pföhler, C, Ruëff, F, Treudler, R, Jaume, ME, Madroñero, A, Perez, MTG, Julia, JC, Plovdiv, CH, Gethings, L, Langridge, J, Adel-Patient, K, Bernard, H, Barcievic-Jones, I, Sokolova, R, Yankova, R, Ivanovska, M, Murdjeva, M, Popova, T, Dermendzhiev, S, Karjalainen, M, Lehnigk, U, Brown, D, Locklear, JC, Locklear, J, Maris, I, Hourihane, J, Ornelas, C, Caiado, J, Ferreira, MB, Pereira-Barbosa, M, Puente, Y, Daza, JC, Monteseirin, FJ, Ukleja-Sokolowska, N, Gawronska-Ukleja, E, Zbikowska-Gotz, M, Bartuzi, Z, Sokolowski, L, Adams, A, Mahon, B, English, K, Gourdon-Dubois, N, Sellam, L, Pereira, B, Michaud, E, Messaoudi, K, Evrard, B, Fauquert, J-L, Palomares, F, Gomez, G, Rodriguez, MJ, Galindo, L, Molina, A, Paparo, L, Mennini, M, Aitoro, R, Wawrzeńczyk, A, Przybyszewski, M, Sarıcoban, HE, Ugras, M, Yalvac, Z, Flokstra-de Blok, BMJ, van der Velde, JL, Vereda, A, Ippolito, C, Traversa, A, Adriano, D, Bianchi, DM, Gallina, S, Decastelli, L, Makatsori, M, Miles, A, Devetak, SP, Devetak, I, Tabet, SA, Trandbohus, JF, Winther, P, Malling, H-J, Hansen, KS, Garvey, LH, Wang, C-C, Cheng, Y-H, Tung, C-W, Dietrich, M, Marenholz, I, Kalb, B, Grosche, S, Blümchen, K, Schlags, R, Price, M, Rietz, S, Esparza-Gordillo, J, Lau, S, Lee, Y-A, Almontasheri, A, Bahkali, MA, Elshorbagi, S, Alfhaid, A, Altamimi, M, Madbouly, E, Al-Dhekri, H, Arnaout, RK, Basagaña, M, Miquel, S, Bartolomé, B, Brix, B, Rohwer, S, Brandhoff, S, Berger, A, Suer, W, Weimann, A, Bueno, C, Martín-Pedraza, L, Abián, S, Segundo-Acosta, PS, López-Rodríguez, JC, Barderas, R, Batanero, E, Cuesta-Herranz, J, Villalba, MT, Correia, M, Benito-Garcia, F, Arêde, C, Piedade, S, Morais-Almeida, M, Hindley, J, Yarham, R, Kuklinska-Pijanka, A, Gillick, D, Patient, K, Chapman, MD, Miranda, A, Matos, E, Sokolova, A, Rao, H, Baricevic-Jones, I, Smith, F, Xue, W, Magnusdottir, H, Vidarsdottir, AG, Lund, S, Jensen, AB, Ludviksson, BR, Simon, R, Elfont, R, Bennett, S, Voyksner, R, de Lurdes Torre, M, Yürek, S, Faber, MA, Bastiaensen, A, Mangodt, E, van Gasse, A, Decuyper, I, Sabato, V, Hagendorens, MM, Bridts, CH, De Clerck, LS, Ebo, D, Schwarz, S, Ziegert, M, Albroscheit, S, Schwager, C, Kull, S, Behrends, J, Röckendorf, N, Schocker, F, Frey, A, Homann, A, Becker, W-M, Jappe, U, Zaabat, N, Osscini, S, Agabriel, C, Sterling, B, Carsin, A, Liabeuf, V, Maćków, M, Zbróg, A, Bronkowska, M, Courtois, J, Gadisseur, R, Bertholet, C, Lukas, P, Cavalier, E, Delahaut, P, Quinting, B, Gertmo, MB, Hasseus, ET, Barzylovych, V, Oliveira, J, Ensina, LF, Aranda, CS, Dopazo, L, Lopez, R, Perez, R, Santos-Diez, L, Bilbao, A, Garcia, JM, Núñez, IG, Mármol, MÁA, Villarejo, MJB, Martos, JAB, Vergara, MS, García, JMI, Michalska, A, Sergiejko, G, Zacniewski, R, Ghiordanescu, I-M, Deaconu, C, Popescu, M, Bumbacea, RS, Ibranji, A, Nikolla, E, Loloci, G, Juel-Berg, N, Larsen, LF, Poulsen, LK, Marcelino, J, Prata, R, Costa, AC, Duarte, F, Neto, M, Santos, J, Pestana, LC, Sampaio, D, Minale, P, Dignetti, P, Bignardi, D, Nedelea, I, Popescu, F-D, Vieru, M, Secureanu, F-A, Ganea, CS, Vieira, M, Silva, JPM, Watts, T, Watts, S, Lomikovska, M, Peredelskaya, M, Nenasheva, N, Filipovic, I, Zivkovic, Z, Filipovic, D, Higgs, J, Warner, A, and Jones, C
- Published
- 2017
185. EAACI Guidelines on Allergen Immunotherapy:Prevention of allergy
- Author
-
Halken, Susanne, Larenas-Linnemann, Desiree, Roberts, Graham, Calderón, Moises A, Angier, Elisabeth, Pfaar, Oliver, Ryan, Dermot D, Agache, Ioana, Ansotegui, Ignacio J I J, Arasi, Stefania, Du Toit, George, Fernandez-Rivas, Montserrat, Geerth van Wijk, Roy, Jutel, Marek, Kleine-Tebbe, Jörg, Lau, Susanne, Matricardi, Paolo M, Pajno, Giovanni B, Papadopoulos, Nikolaos G, Penagos, Martin, Santos, Alexandra F, Sturm, Gunter J, Timmermans, Frans, Van Ree, R, Varga, Eva-Maria, Wahn, Ulrich, Kristiansen, Maria, Dhami, Sangeeta, Sheikh, Aziz, Antonella, Muraro, Halken, Susanne, Larenas-Linnemann, Desiree, Roberts, Graham, Calderón, Moises A, Angier, Elisabeth, Pfaar, Oliver, Ryan, Dermot D, Agache, Ioana, Ansotegui, Ignacio J I J, Arasi, Stefania, Du Toit, George, Fernandez-Rivas, Montserrat, Geerth van Wijk, Roy, Jutel, Marek, Kleine-Tebbe, Jörg, Lau, Susanne, Matricardi, Paolo M, Pajno, Giovanni B, Papadopoulos, Nikolaos G, Penagos, Martin, Santos, Alexandra F, Sturm, Gunter J, Timmermans, Frans, Van Ree, R, Varga, Eva-Maria, Wahn, Ulrich, Kristiansen, Maria, Dhami, Sangeeta, Sheikh, Aziz, and Antonella, Muraro
- Abstract
Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for prevention of i) development of allergic comorbidities in those with established allergic diseases, ii) development of first allergic condition and iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, which involved a multi-disciplinary expert working group, a systematic review of the underpinning evidence and external peer-review of draft recommendations. Our key recommendation is that a three year course of subcutaneous or sublingual AIT can be recommended for children and adolescents with moderate to severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to two years post-AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than two years post AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease or for prevention of allergic co-morbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease modifying treatment exists but there is an urgent need for more high-quality clinical trials.
- Published
- 2017
186. A new framework for the documentation and interpretation of oral food challenges in population-based and clinical research
- Author
-
Grabenhenrich, L B, Reich, A, Bellach, J, Trendelenburg, V, Sprikkelman, A B, Roberts, G, Grimshaw, K E C; https://orcid.org/0000-0003-3649-7963, Sigurdardottir, S, Kowalski, M L, Papadopoulos, N G, Quirce, S, Dubakiene, R, Niggemann, B, Fernández-Rivas, M, Ballmer-Weber, B, van Ree, R, Schnadt, S, Mills, E N C, Keil, T, Beyer, K, Grabenhenrich, L B, Reich, A, Bellach, J, Trendelenburg, V, Sprikkelman, A B, Roberts, G, Grimshaw, K E C; https://orcid.org/0000-0003-3649-7963, Sigurdardottir, S, Kowalski, M L, Papadopoulos, N G, Quirce, S, Dubakiene, R, Niggemann, B, Fernández-Rivas, M, Ballmer-Weber, B, van Ree, R, Schnadt, S, Mills, E N C, Keil, T, and Beyer, K
- Published
- 2017
187. Poster
- Author
-
Fiebig, H., Weber, B., Cromwell, O., Jutel, M., Fiedler, G., Hanschmann, H., Hansen, I., Stuck, B. A., Hörmann, K., Klimek, L., Jappe, U., Hoffmann, M., Burow, G., Mühlmeier, G., Maier, H., Mušič, E., Košnik, M., Piller, M., Drachenberg, K. J., Urban, E., Schenn, A., Ruëff, F., Weimer, G., Przybilla, B., Sieber, W., Schoppelrey, V., Pfeifer, M., Steiß, J. O., Lindemann, H., Wolf, H., Schnitker, J., Petermann, F., Bergmann, K. C., Zwacka, G., Steinert, B., Markert, U. R., Bijlsma, P. B., Backhaus, B., Weidenhiller, M., Donhauser, N., Hahn, E. G., Raithel, M., Erkelens, W., Hommes, D., Bruno, M., Akkerdaas, J., van Ree, R., Groot, J. A., Taminiau, J. A. J. M., Meinardi, M. M. H. M., Borowski, C., Schäfer, T., Eberhardt, F., Lepp, U., Becker, W.-M., Zabel, P., Hipler, U.-C., Spoo, J., Bauer, A., Elsner, P., Kuefner, M. A., Schwelberger, H. G., Lange, L., Rietschel, E., Riffelmann, F., Lauter, H., Müller, K.-M., Tränkner, A., Mach, K., Reulbach, U., Geyer, D., Leis, B., Ziegert, M., Ahlert, I., Deichmann, K. A., Heinzmann, A., Allmers, H., Beezhold, D., Hamilton, R. G., Sutherland, E. R., Schwanitz, H. J., Scherer, K., Bircher, A. J., Dymek, S., Lex, C., Balzer, S., Schuster, A., Hülsmeier, L., Barker, M., Müller-Lux, A., Göen, T., Koll, W., Koschel, D., Müller-Wening, D., Kütting, B., Janicke, N., Schippke, D., Langer, C., Schulz, T. G., Turowski, S., Drexler, H., Hallier, E., Bickeböller, H., Heutelbeck, A. R. R., Lässig, W., Nordwig, A., Dellweg, D., Schwarz, H., Goldmann, R., Lorenz, C., Achtzehn, U., Stehle, R., Keiper, B., Jilge, B., Beier, L., Schmidt, E. W., van Kampen, V., Haamann, F., Merget, R., Sander, I., Raulf-Heimsoth, M., Rabstein, S., Brüning, T., Ahrens, T., Muesken, H., Bergmann, K.-Ch., Vetter, M., Heitmann, M., Hunzelmann, N., Schuster, J., Kadar, J., Kespohl, S., Petersen, A., Meyer, H. E., Sickmann, A., Kleber, N., Hinrichs, J., Schocker, F., Becker, W. M., Rozynek, P., Dresselhaus, T., Reuter, B., Henzgen, M., Fahlbusch, B., Rudeschko, O., Schlenvoigt, G., Kroegel, C., Rihs, H.-P., Gaspar, Â., Pires, G., Hohenstein, E., Fiedler, E.-M., v. Pelchrzim, R., Focke, M., Zuberbier, T., Worm, M., Janowska, E., Grycmacher-Łapko, V., Kurek, M., Lippert, U., Niedenführ, S., Fuchs, T., Ludwig, A., Koch, A., Balda, B.-R., Oestmann, E., Philipp, S., Spornraft-Ragaller, P., Hammermann, J., Meurer, M., Ott, H., Wurpts, G., Krieg, R., Al Masaoudi, T., Joussen, S., Kiehl, K., Neis, M., Merk, H. F., Baron, J. M., Schmengler, J., John, S. M., Blaschke, V., Bonnekoh, B., Holzamer, N., Schmidt, U., Ambach, A., Oppermann, H., Thriene, B., Gollnick, H., Kraus, T., Häberle, M., Hoopmann, M., Hehl, O., Werfel, T., Heidrich, S., Kelber, J., Hünecke, P., Kasche, A., Klaus, S., Thiel, M., Buters, J., Weichenmeier, I., Ring, J., Traidl-Hoffmann, C., Behrendt, H., Krämer, U., Lau, S., Kim, S., Mahling, H., Schulz, G., Keil, T., Wahn, U., Mock, B., Kugler, J., Cremer, R., Sandner, B., Kaiser, F., Herbst, R. A., Wahl, R., Suck, R., Kügler, K., Frosch, P. J., Nabe, A., Konturek, P., Simon, K., Kressel, J., Nägel, A., Wilken, V., Strehfeld, T., Neubert, K., Pieper, B., Kuhn, M., Winterkamp, S., Pacurar, A., Senger, D., Beskitas, E., Dorrmann, H., Mueller, M. W., Harwanegg, C., Hiller, R., Kinne, R. W., Schröder, C. M., Mahler, V., Schröder, A., Erdmann, S., Schultis, H. W., Buchwald, F., Hampel, W., Maiss, J., Naegel, A., Zahradnik, E., Doekes, G., Runge, D. M., Schwertner, H., Grize, L., Schindler, C., Surber, Ch., Böckelmann, R., Horn, T., Breithaupt, S., Thiele, J. J., Gutermuth, J., Jakob, T., Heinzelmann, J., Varosi, F., Debevc, F., Pöhlmann, T. G., Seyfarth, L., Kindt, F., Löser, C., Niemeier, V., Gieler, U., Kummer, W., Haberberger, R. V., Klockenbring, T., Stöcker, M., Huhn, M., Bauer, R., Goerlich, R., Fischer, R., Barth, S., Suchodolska, A., Soost, S., Bayerl, C., Ludwig, B., Gancs, P., Häusermann, P., Harr, T., Müller, M., Sachs, B., Riegel, S., Schichler, D., Schrooten, J., Heussen, N., Hilgers, R.-D., Seo, J. W., Franke, I., and Strauss, R.
- Subjects
SIT und Insektengiftallergie ,Immunology and Allergy - Published
- 2004
- Full Text
- View/download PDF
188. Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy
- Author
-
Zuidmeer-Jongejan, L. Huber, H. Swoboda, I. Rigby, N. Versteeg, S.A. Jensen, B.M. Quaak, S. Akkerdaas, J.H. Blom, L. Asturias, J. Bindslev-Jensen, C. Bernardi, M.L. Clausen, M. Ferrara, R. Hauer, M. Heyse, J. Kopp, S. Kowalski, M.L. Lewandowska-Polak, A. Linhart, B. Maderegger, B. Maillere, B. Mari, A. Martinez, A. Mills, E.N.C. Neubauer, A. Nicoletti, C. Papadopoulos, N.G. Portoles, A. Ranta-Panula, V. Santos-Magadan, S. Schnoor, H.J. Sigurdardottir, S.T. Stahl-Skov, P. Stavroulakis, G. Stegfellner, G. Vázquez-Cortés, S. Witten, M. Stolz, F. Poulsen, L.K. Fernandez-Rivas, M. Valenta, R. Van Ree, R.
- Abstract
Background: The FAST (food allergy-specific immunotherapy) project aims at developing safe and effective subcutaneous immunotherapy for fish allergy, using recombinant hypoallergenic carp parvalbumin, Cyp c 1. Objectives: Preclinical characterization and good manufacturing practice (GMP) production of mutant Cyp (mCyp) c 1. Methods:Escherichia coli-produced mCyp c 1 was purified using standard chromatographic techniques. Physicochemical properties were investigated by gel electrophoresis, size exclusion chromatography, circular dichroism spectroscopy, reverse-phase high-performance liquid chromatography and mass spectrometry. Allergenicity was assessed by ImmunoCAP inhibition and basophil histamine release assay, immunogenicity by immunization of laboratory animals and stimulation of patients' peripheral blood mononuclear cells (PBMCs). Reference molecules were purified wild-type Cyp c 1 (natural and/or recombinant). GMP-compliant alum-adsorbed mCyp c 1 was tested for acute toxicity in mice and rabbits and for repeated-dose toxicity in mice. Accelerated and real-time protocols were used to evaluate stability of mCyp c 1 as drug substance and drug product. Results: Purified mCyp c 1 behaves as a folded and stable molecule. Using sera of 26 double-blind placebo-controlled food-challenge-proven fish-allergic patients, reduction in allergenic activity ranged from 10-to 5,000-fold (1,000-fold on average), but with retained immunogenicity (immunization in mice/rabbits) and potency to stimulate human PBMCs. Toxicity studies revealed no toxic effects and real-time stability studies on the Al(OH)3-adsorbed drug product demonstrated at least 20 months of stability. Conclusion: The GMP drug product developed for treatment of fish allergy has the characteristics targeted for in FAST: i.e. hypoallergenicity with retained immunogenicity. These results have warranted first-in-man immunotherapy studies to evaluate the safety of this innovative vaccine. © 2015 S. Karger AG, Basel.
- Published
- 2015
189. How much is too much? Threshold dose distributions for 5 food allergens
- Author
-
Ballmer-Weber, B.K. Fernandez-Rivas, M. Beyer, K. Defernez, M. Sperrin, M. Mackie, A.R. Salt, L.J. Hourihane, J.O. Asero, R. Belohlavkova, S. Kowalski, M. De Blay, F. Papadopoulos, N.G. Clausen, M. Knulst, A.C. Roberts, G. Popov, T. Sprikkelman, A.B. Dubakiene, R. Vieths, S. Van Ree, R. Crevel, R. Mills, E.N.C.
- Abstract
Background Precautionary labeling is used to warn consumers of the presence of unintended allergens, but the lack of agreed allergen thresholds can result in confusion and risk taking by patients with food allergy. The lack of data on threshold doses below which subjects are unlikely to react is preventing the development of evidence-based allergen management strategies that are understood by clinician and patient alike. Objective We sought to define threshold dose distributions for 5 major allergenic foods in the European population. Methods Patients with food allergy were drawn from the EuroPrevall birth cohort, community surveys, and outpatient clinic studies and invited to undergo a food challenge. Low-dose, double-blind, placebo-controlled food challenges were undertaken with commercially available food ingredients (peanut, hazelnut, celery, fish, and shrimp) blinded into common matrices. Dose distributions were modeled by using interval-censoring survival analysis with 3 parametric approaches. Results Of the 5 foods used for challenge, 4 produced similar dose distributions, with estimated doses eliciting reactions in 10% of the allergic population (ED10), ranging from 1.6 to 10.1 mg of protein for hazelnut, peanut, and celery with overlapping 95% CIs. ED10 values for fish were somewhat higher (27.3 mg of protein), although the CIs were wide and overlapping between fish and plant foods. Shrimp provided radically different dose distributions, with an ED10 value of 2.5 g of protein. Conclusion This evidence base will contribute to the development of reference doses and action levels for allergens in foods below which only the most sensitive subjects might react. © 2014 American Academy of Allergy, Asthma & Immunology.
- Published
- 2015
190. Hazelnut allergy across Europe dissected molecularly: A EuroPrevall outpatient clinic survey
- Author
-
Datema, M.R. Zuidmeer-Jongejan, L. Asero, R. Barreales, L. Belohlavkova, S. De Blay, F. Bures, P. Clausen, M. Dubakiene, R. Gislason, D. Jedrzejczak-Czechowicz, M. Kowalski, M.L. Knulst, A.C. Kralimarkova, T. Le, T.-M. Lovegrove, A. Marsh, J. Papadopoulos, N.G. Popov, T. Del Prado, N. Purohit, A. Reese, G. Reig, I. Seneviratne, S.L. Sinaniotis, A. Versteeg, S.A. Vieths, S. Zwinderman, A.H. Mills, C. Lidholm, J. Hoffmann-Sommergruber, K. Fernández-Rivas, M. Ballmer-Weber, B. Van Ree, R.
- Subjects
food and beverages - Abstract
Background Hazelnut allergy is birch pollen-driven in Northern/Western Europe and lipid transfer protein-driven in Spain and Italy. Little is known about other regions and other allergens. Objective Establishing a molecular map of hazelnut allergy across Europe. Methods In 12 European cities, subjects reporting reactions to hazelnut (n = 731) were evaluated and sensitization to 24 foods, 12 respiratory allergen sources, and latex was tested by using skin prick test and ImmunoCAP. A subset (124 of 731) underwent a double-blind placebo-controlled food challenge to hazelnut. Sera of 423 of 731 subjects were analyzed for IgE against 7 hazelnut allergens and cross-reactive carbohydrate determinants by ImmunoCAP. Results Hazelnut allergy was confirmed in 70% of those undergoing double-blind placebo-controlled food challenges. Birch pollen-driven hazelnut sensitization (Cor a 1) dominated in most cities, except in Reykjavik, Sofia, Athens, and Madrid, where reporting of hazelnut allergy was less frequent anyhow. In Athens, IgE against Cor a 8 dominated and strongly correlated with IgE against walnut, peach, and apple and against Chenopodium, plane tree, and mugwort pollen. Sensitization to seed storage proteins was observed in less than 10%, mainly in children, and correlated with IgE to nuts, seeds, and legumes. IgE to Cor a 12, observed in all cities (10% to 25%), correlated with IgE to nuts, seeds, and pollen. Conclusions In adulthood, the importance of hazelnut sensitization to storage proteins, oleosin (Cor a 12), and Cor a 8 is diluted by the increased role of birch pollen cross-reactivity with Cor a 1. Cor a 8 sensitization in the Mediterranean is probably driven by diet in combination with pollen exposure. Hazelnut oleosin sensitization is prevalent across Europe; however, the clinical relevance remains to be established. © 2015 American Academy of Allergy, Asthma & Immunology.
- Published
- 2015
191. From the Sugar Platform to biofuels and biochemicals : Final report for the European Commission Directorate-General Energy
- Author
-
Taylor, R., Nattrass, L., Alberts, G., Robson, P., Chudziak, C., Bauen, A., Libelli, I.M., Lotti, G., Prussi, M., Nistri, R., Chiaramonti, D., lópez-Contreras, A.M., Bos, H.L., Eggink, G., Springer, J., Bakker, R., and van Ree, R.
- Subjects
Bio Process Engineering ,chemicaliën uit biologische grondstoffen ,karteringen ,biobased economy ,chemie op basis van biologische grondstoffen ,biobased chemicals ,chemische industrie ,suiker ,case studies ,europa ,gevalsanalyse ,BBP Bioconversion ,surveys ,sugar ,BBP Biorefinery & Sustainable Value Chains ,biobased chemistry ,Biobased Products ,chemical industry ,europe - Abstract
Numerous potential pathways to biofuels and biochemicals exist via the sugar platform1. This study uses literature surveys, market data and stakeholder input to provide a comprehensive evidence base for policymakers and industry – identifying the key benefits and development needs for the sugar platform. The study created a company database for 94 sugar-based products, with some already commercial, the majority at research/pilot stage, and only a few demonstration plants crossing the “valley of death”. Case studies describe the value proposition, market outlook and EU activity for ten value chains (acrylic, adipic & succinic acids, FDCA, BDO, farnesene, isobutene, PLA, PHAs and PE). Most can deliver significant greenhouse savings and drop-in (or improved) properties, but at an added cost to fossil alternatives. Whilst significant progress has been made, research barriers remain around lignocellulosic biomass fractionation, product separation energy, biological inhibition, chemical selectivity and monomer purity, plus improving whole chain process integration. An assessment of EU competitiveness highlights strengths in R&D, but a lack of strong commercial activity, due to the US, China and Brazil having more attractive feedstock and investment conditions. Further policy development, in particular for biochemicals, will be required to realise a competitive European sugar-based bioeconomy.
- Published
- 2015
192. D5.3 Summary report on how sustainability aspects of introduction bioeconomy value chains are currently considered
- Author
-
Panoutsou, Calliope, Alakangas, Eija, Annevelink, E., Breshkov, Ivan, Cosic, Boris, Elbersen, B.S., Elbersen, H.W., Fritsche, Uwe R., Grammelis, Panagiotis, Iriarte, Leire, Karampinis, Manolis, Kavalov, Boyan, Kayam, Yildirim, Lindner, Marcus, Pelkmans, Luc, Sanchez, David, Stojiljkovic, Dragoslava, Wenzelides, Ludger, and van Ree, R.
- Subjects
Earth Observation and Environmental Informatics ,Aardobservatie en omgevingsinformatica ,Life Science ,BBP Biorefinery & Sustainable Value Chains - Published
- 2015
193. Framework and Examples for the Life Cycle Based Assessment of Biorefineries in IEA Bioenergy Task 42 Biorefining
- Author
-
Jungmeier, G., Van Ree, R., De Jong, E., Sichnothe, H., De Bari, I., Joergensen, H., Wellisch, M., Clancy, M., Bell, G., Spaeth, J., Torr, K., and Kimura, S.
- Subjects
Biomass - Abstract
The IEA Bioenergy Task 42 “Biorefining” with its 11 member countries (A, AUS, CA, DK, G, I, IR, J, NL, NZ, USA) has the following definition on biorefining: “Biorefining is the sustainable processing of biomass into a spectrum of bio-based products (food, feed, chemicals, and materials) and bioenergy (biofuels, power and/or heat)”. Based on the activities in the 11 member countries of Task 42 the assessment framework is developed based on a life cycle basis to cover all relevant issues from the production, operation and end of life phase of the whole value chain of various biorefineries. The framework follows the following hierarchy procedure: 1) biorefinery classification and assessment of the technologies and processes using the 9 levels of the “Technology Readiness Level (TRL)”. 2) Calculation of most relevant economic data using the approach of Life Cycle Costing (LCC). 3) Application of Life Cycle Assessment (LCA) to assess the most relevant environmental aspects. 4) Screening of relevant social issues in a Social Life Cycle Assessment (sLCA). 5) Integration of these aspects in the approach of Life Cycle Sustainability Assessment (LCSA) 6) Identification of most attractive industry sectors (“Hot Spots”) for the integration of biorefineries in the existing industrial infrastructure 7) Highlighting necessary R&D demand for commercialization until 2025, 8) Concluding on the possible future role in a BioEconomy in a regional, national and international context. A compact format is developed to present the results of the assessing framework. The framework is applied to different biorefinery concepts. The results assist various stakeholders in finding their position on biorefining in a future biobased economy while minimizing unexpected technical, economic and financial risks by significantly contributing to the development of a BioEconomy., Proceedings of the 23rd European Biomass Conference and Exhibition, 1-4 June 2015, Vienna, Austria, pp. 1353-1358
- Published
- 2015
- Full Text
- View/download PDF
194. Harvesting, logistics and upgrading of herbaceous biomass from verges and natural areas for use in thermal conversion : TKI BBE Park Cuijk
- Author
-
Elbersen, H.W., Keijsers, E.R.P., Bakker, R., op den Kamp, R.G.M., Holshof, G., Spijker, J.H., van Ree, R., Arkestijn, Karlijn, van Schijndel, Daan, Haasnoot, Kees, Remmelink, Bert-Erik, Bakker, P., Massop, Hans, and Quik, Jan
- Subjects
grasmaaisel ,Animal Nutrition ,biomass ,biomassa ,verbranding ,Nature and society ,biobased economy ,grass clippings ,netherlands ,cogeneration ,bioenergy ,sustainability ,Diervoeding ,bio-energie ,warmtekrachtkoppeling ,nederland ,duurzaamheid (sustainability) ,BBP Biorefinery & Sustainable Value Chains ,combustion ,Natuur en samenleving - Abstract
The main goal of this project was to analyse if it is technically possible, environmentally favourable and economically profitable to use herbaceous biomass from verges (roadsides) and natural areas as raw material for combustion in the Cuijk facility of Essent for the production of CHP (combined heat and power).
- Published
- 2015
195. International Archives of Allergy and Immunology / Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy
- Author
-
Zuidmeer-Jongejan, Laurian, Huber, H, Swoboda, Ines, Rigby, N, Versteeg, SA, Jensen, BM, Quaak, S, Akkerdaas, JH, Blom, L, Asturias, J, Bindslev-Jensen, C, Bernardi, ML, Clausen, M, Ferrara, R, Hauer, M, Heyse, J, Kopp, S, Kowalski, ML, Lewandowska-Polak, A, Linhart, B, Maderegger, B, Maillere, B, Mari, A, Martinez, A, Mills, EN, Neubauer, A, Nicoletti, C, Papadopoulos, NG, Portoles, A, Ranta-Panula, V, Santos-Magadan, S, Schnoor, HJ, Sigurdardottir, ST, Stahl-Skov, P, Stavroulakis, G, Stegfellner, G, Vázquez-Cortés, S, Witten, M, Stolz, F, Poulsen, LK, Fernandez-Rivas, M, Valenta, Rudolf, and van Ree, R
- Published
- 2015
- Full Text
- View/download PDF
196. IgE recognition patterns in peanut allergy are age dependent: Perspectives of the EuroPrevall study
- Author
-
Ballmer-Weber, B.K. Lidholm, J. Fernández-Rivas, M. Seneviratne, S. Hanschmann, K.-M. Vogel, L. Bures, P. Fritsche, P. Summers, C. Knulst, A.C. Le, T.-M. Reig, I. Papadopoulos, N.G. Sinaniotis, A. Belohlavkova, S. Popov, T. Kralimarkova, T. De Blay, F. Purohit, A. Clausen, M. Jedrzejczak-Czechowcz, M. Kowalski, M.L. Asero, R. Dubakiene, R. Barreales, L. Clare Mills, E.N. Van Ree, R. Vieths, S.
- Subjects
food and beverages - Abstract
Background We tested the hypothesis that specific molecular sensitization patterns correlate with the clinical data/manifestation in a European peanut-allergic population characterized under a common protocol. Methods Sixty-eight peanut-allergic subjects and 82 tolerant controls from 11 European countries were included. Allergy to peanut and lowest symptom-eliciting dose was established by double-blind placebo-controlled food challenge in all but anaphylactic subjects. Information of early or late (before or after 14 years of age) onset of peanut allergy was obtained from standardized questionnaires. IgE to peanut allergens rAra h 1-3, 6, 8-9, profilin and CCD was determined using ImmunoCAP. Results Seventy-eight percent of peanut allergics were sensitized to peanut extract and 90% to at least one peanut component. rAra h 2 was the sole major allergen for the peanut-allergic population. Geographical differences were observed for rAra h 8 and rAra h 9, which were major allergens for central/western and southern Europeans, respectively. Sensitization to rAra h 1 and 2 was exclusively observed in early-onset peanut allergy. Peanut-tolerant subjects were frequently sensitized to rAra h 8 or 9 but not to storage proteins. Sensitization to Ara h 2 ≥ 1.0 kUA/l conferred a 97% probability for a systemic reaction (P = 0.0002). Logistic regression revealed a significant influence of peanut extract sensitization and region on the occurrence of systemic reactions (P = 0.0185 and P = 0.0436, respectively). Conclusion Sensitization to Ara h 1, 2 and 3 is usually acquired in childhood. IgE to Ara h 2 ≥ 1.0 kUA/l is significantly associated with the development of systemic reactions to peanut. © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
- Published
- 2015
197. Environmental and Genetic Factors in Allergy and Clinical Immunology
- Author
-
van Ree R., Ring J., MARONE, GIANNI, van Ree, R., Ring, J., and Marone, Gianni
- Published
- 2009
198. Opisthorchis felineus negatively associates with skin test reactivity in Russia-EuroPrevall-International Cooperation study
- Author
-
Fedorova, O. S., primary, Janse, J. J., additional, Ogorodova, L. M., additional, Fedotova, M. M., additional, Achterberg, R. A., additional, Verweij, J. J., additional, Fernández-Rivas, M., additional, Versteeg, S. A., additional, Potts, J., additional, Minelli, C., additional, van Ree, R., additional, Burney, P., additional, and Yazdanbakhsh, M., additional
- Published
- 2017
- Full Text
- View/download PDF
199. EAACI Molecular Allergology User's Guide
- Author
-
Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.
- Published
- 2016
200. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project
- Author
-
Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.